TREATMENT OF CANCER AND NEUROLOGICAL DISEASES

Abstract: The present invention relates to a nucleic acid molecule and the protein encoded thereby absence of which is associated with oral and other cancers and lack of neurogenesis. The invention also provides antibodies and the use of these products as therapeutic and/or diagnostic agents in gene therapy and/or tissue repair.

Description: Treatment of Cancer and Neurological Diseases The present invention relates to the isolation of a nucleic acid molecule and the protein encoded thereby; antibodies raised thereto and the use of these products as therapeutic and/or diagnostic agents particularly, but not exclusively, in gene therapy and/or tissue repair such as, without limitation enhancing neuronal repair /regeneration and in the treatment of cancer. Background to the Invention Oral cancer has significant morbidity and mortality rates. In England and Wales the 5-year survival is around 50%. Globally, oral cancer is one of most common cancers and in some parts of the world it is the most prevalent of all cancer types. For example, in India and Sri Lanka oral cancer accounts for up to 40% of all diagnosed cancers. In addition to geographic "hot spots", there seems to be a rising trend in the increased incidence of oral cancers in many developed nations. Recent advances in cancer management have failed to impact significantly on the outcome of oral cancer. Surgery and radiotherapy remain the principle forms of • treatment with a limited role for chemotherapy. Treatment can be mutilating and is associated with high morbidity that significantly impacts on the quality of life. Speech, swallowing and taste can be markedly impaired after treatment. New treatment modalities are required for oral cancer therapy. Statement of the Invention We have identified a gene, from human chromosome 8p23, which is deleted in oral cancer. The gene was found to have distant similarity to the gene encoding the protein "tolloid"; and contains multiple Sushi and CUB domains. We believe that this gene may have utility in diagnosis and gene therapy applications for oral and other cancers. Moreover, and surprisingly, the gene from human chromosome 8p23 may also be implicated in aspects of the developmental regulation of neurogenesis. We base this belief on our observations that the gene has similarity with tolloid, an important developmental gene, and the fact that it is located in the autosomal recessive microcephaly locus, MCPHl, critical region. Sequence variations in this gene can segregate with microcephaly in some families. It therefore may have utility in the diagnosis and therapy of microcephaly, as well as therapies directed to neuronal repair and regeneration, including those utilising stem cells/neural progenitor cells. Having identified this gene we believe that a further use is in the production of transgenic animals. These may have an increased predisposition to oral cancer and/or have decreased or potentially increased neocortex. Such animals would be useful not only as models of oral cancer for the evaluation of novel therapeutics but also to improve understanding of neurological developmental abnormalities. They would also serve as models to test novel therapeutics for neuronal regeneration. According to a first aspect of the present invention there is provided an isolated nucleic acid selected from the group consisting of: (a) DNA having the nucleotide sequence given herein as any one of SEQ „ ID NOS:l TO 8; (b) nucleic acids which hybridize to DNA of (a) above (e.g., under stringent conditions); (c) nucleic acids having between 75-95% homology with any one of the nucleotide sequences given herein as SEQ ID NOS:l to 8; and (d) nucleic acids which differ from the DNA of (a), (b) or (c) above due to the degeneracy of the genetic code. DNAs of the present invention include those coding for proteins homologous to, and having essentially the same biological properties as, the proteins disclosed herein, and particularly the DNA disclosed herein as any one of SEQ ID NOS:l to 8 and encoding the proteins given herein as SEQ ID NOS:9 to 16 This definition is intended to encompass natural allelic variations therein. Thus, isolated DNA or cloned genes of the present invention can be of any species of origin, including mouse, rat, rabbit, cat, porcine, and human, but are preferably of-mammalian origin. Thus, DNAs which hybridize to DNA disclosed herein as any one of SEQ ID NOS:l to 8 (or fragments or derivatives thereof which serve as hybridization probes as discussed below) and which code on expression for a protein of the present invention (e.g., a protein according to any one of SEQ ID NOS: 9 to 16), i.e. the protein lack of which is associated with oral or other cancers and/or lack of neurogenesis. of the present invention are to be included in the definition. Conditions which will permit other DNAs which code on expression for a protein of the present invention to hybridize to the DNAs of SEQ ID NO:l to 8 disclosed herein can be determined in accordance with known techniques. For example, hybridization of such sequences may be carried out under conditions of reduced stringency, medium stringency or even stringent conditions (e.g., conditions represented by a wash stringency of 35-40% Formamide with 5x Denhardt's solution, 0.5% SDS and lx SSPE at 37°C; conditions represented by a wash stringency of 40-45% Formamide with 5x Denhardt's solution, 0.5% SDS, and lx SSPE at 42°C; and conditions represented by a wash stringency of 50% Formamide with 5x Denhardt's solution, 0.5% SDS and lx SSPE at 42°C, respectively) to DNAs of-SEQ ID NO:l to 8 disclosed herein in a standard hybridization assay. See, e.g., J. Sambrook et al., Molecular Cloning, A Laboratory Manual (2d Ed. 1989) (Cold Spring Harbor Laboratory). In general, sequences which code for proteins of the present invention and which hybridize to the DNAs of SEQ ID NO:l to 8 disclosed herein will be at least preferably 75% homologous, 85% homologous, and even 95% homologous or more with SEQ ID NO:l to 8. Further, DNAs which code for proteins of the present invention, or DNAs which hybridize to that given as any one of SEQ ID NOS:l to 8, but which differ in codon sequence from SEQ ID NO:l to 8 due to the degeneracy of the genetic code, are also an aspect of this invention. The degeneracy of the genetic code, which allows different nucleic acid sequences to code for the same protein or peptide, is well known in the literature. See, e.g., U.S. Patent No. 4,757,006 to Toole et al. at Col. 2, Table 1. According to a yet further aspect of the invention there is provided a nucleic acid molecule which encodes a protein lack of which is associated with oral or other cancers and/or lack of neurogenesis and comprises a nucleotide sequence which hybridises to the nucleic acid of any one of SEQ ID NOS:l to 8 under high stringency conditions. Preferably, hybridisation occurs under stringent conditions such as 1 x SSC, 0.1% SDS at 65 °C. Preferably, the nucleic acid is mammalian in origin, for example it may be human or murine. Preferably, the nucleic acid of the present invention is at least 2kb and up to 12 kb and may be, for example 5.5kb. The nucleic acid being located on chromosome 8p23. According to a yet further aspect of the invention there is provided use of the nucleic acid of the present invention, in determining loss of genomic material or loss of expression of mRNA in selected target tissue(s) for diagnosing oral or other cancers and/or neurological developmental abnormalities. According to a yet further aspect of the invention there is provided use of the nucleic acids of the present invention, in determining the presence of mutants in the DNA and thus diagnosing patients suffering from oral or other cancers and/or neurological developmental abnormalities. According to a further aspect of the invention there is provided a polypeptide, or a protein comprising an epitope for an antibody or a protein modified by one or more amino acid modifications and comprising an epitope, or a fragment modified or unmodified comprising an eptitope for a protein lack of which is associated with oral or other cancers and/or neurogenesis and encoded by SEQ ID NO:9 to 16. Ideally the polypeptide is encoded by the nucleic acid molecule of any one of SEQ ID NO:l to 8. According to a yet further aspect of the invention there is provided a polypeptide or protein encoded by the nucleic acids of the present invention, preferably the sequences of which are as set forth in SEQID NOS:9 to 16. According to a yet further aspect of the invention there is provided a delivery vehicle comprising the isolated nucleic acid molecule or polypeptide or protein of the present invention or antibodies to these. Reference herein to the term delivery vehicle is intended to include any vector whether a viral vector or otherwise for example, without limitation, an adenovirus, a retrovirus, a herpesvirus, a plasmid, a phage, a phagemid or a liposome. Ideally said delivery vehicle is adapted for administration, for example, but without limitation, by suitable formulation into a suspension. More preferably, said delivery vehicle is adapted to deliver said nucleic acid molecule or polypeptide to selected tissue. Thus the delivery vehicle is provided with means to facilitate its binding and/or penetration to a specific target site. The nature of the means comprises conventional technologies well known to those skilled in the art for example, without limitation, in the instance where the delivery vehicle is a viral vector said viral vector is provided with surface protein adapted to ensure the viral vector binds to and/or penetrates specific target tissues. Alternatively, gene expression of any one of SEQ ID NOS.T to 8 may be under the control of a tissue specific promoter. Thus, in this way, the nucleic acid molecule or peptide, fragments or derivatives thereof of the invention can be used in gene therapy treatments. According to a yet further aspect of the invention there is provided antibodies raised against the polypeptide, fragment or derivative thereof, of the invention. Ideally the antibodies are monoclonal and more ideally genetically engineered to be humanised. It will be apparent to those skilled in the art that the antibodies of the invention can be used to determine the expression of the polypeptide of the invention in selected target tissue and thus aid in the diagnosis of patients suffering from oral cancers and/or neurological disorders. According to a yet further aspect of the invention there is provided use of antibodies, fragments or derivatives thereof in diagnosis/detection/identification of oral or other cancers and/or neurological disorders. It will be appreciated that the antibodies as well as the fragments or derivatives of the antibodies recognise the epitope and are capable of binding to the antigenic protein. Also useful are recombinant antibodies. The invention also includes antibodies and other compositions of matter which are specific binding partners of the polyamino acids of the present invention. Reference herein to polyamino acids is intended to include proteins and polypeptides. The invention further provides for assays using the antibodies of the present invention to detect individuals suffering from or having a predisposition towards oral or other cancers and/or neurologiacl disorders. The assays may employ labelling, for example radioactive labels, enzymes, fluorescent compounds, chemiluminescent compounds, bioluminescent compounds and metal chelates. Typical assays include assays known to the skilled person for quantitative or non- quantitative detection of antibodies and all involve contacting antigenic polypeptides of the present invention with a sample. The assay may involve for example and without limitation any one or more of the following techniques, RIA, EIA, ELISA, sandwich assays. According to a yet further aspect of the invention there is provided a method for the treatment of oral cancers and/or neurological disorders comprising administering to a patient suffering from these conditions the nucleic acid molecule or polypeptide/protein of the present invention. Preferably, the nucleic acid molecule and/or polypeptide/protem is administered by the incorporation of said nucleic acid molecule or polypeptide/protein into a delivery vehicle as herein described and ideally the method of treatment involves the use of gene therapy. According to a yet further aspect of the invention there is the nucleic acid and/or protein, as herein before described for use as a pharmaceutical. According to a yet further aspect of the invention there is provided use of the nucleic acid and/or protein of the present invention for the manufacture of a medicament for the treatment of oral or other cancers and/or neurological disorders. According to a yet further aspect of the invention there is provided a method of producing a transgenic non-human animal comprising disrupting a gene, or the effective part thereof, the gene comprising the nucleic acid of the present invention and/or the protein or effective part thereof of the present invention. Reference herein to disruption is intended to include complete or partial disruption of expression of the protein such that the transgenic animal is unable to express levels of the said protein that are typically found in normal individuals as compared with those suffering from oral cancer and/or neurological developmental abnormalities. Preferably, the transgenic mammal is a rodent and ideally a mouse and more preferably the gene encoding the protein lack of which is associated with oral cancer and/or neurogenesis is the nucleic acid molecule or fragment or derivative thereof as set forth in any one of SEQ ID NOS:l to 8. According to a yet further aspect of the invention there is provided a transgenic non- human animal whose somatic and germ cells do not contain or express a gene encoding a nucleic acid, or a nucleic acid which hybridises under high stringency conditions to, the sequence as set forth in any one of SEQ ID NOS:l r to 8, the gene having been deleted, mutated or disrupted in the animal or an ancestor of the animal at an embryonic stage and wherein the gene may be operably linked to an inducible promoter element. Preferably, the transgenic mammal is a rodent and ideally a mouse. According to a yet further aspect of the invention there is provided a reporter gene construct based on the promoter region of the gene, or effective part thereof, encoded by any one of SEQ ID NOS: 1 to 8 i.e. the nucleic acid of the present invention. According to a yet further aspect of the invention there is provided use of a reporter gene construct based on the promoter region of a gene, or effective part thereof, encoded by any one of SEQ ID NOS:l to 8 in the detection/screening of pharmaceuticals and/or other compounds. According to a yet further aspect of the invention there is provided a method of determining the presence of or predisposition towards oral or other cancers and/or neurological developmental abnormalities comprising: (i) identifying the regions of said DNA sample that contain the nucleic acid according to the present invention; (ii) individually hybridising parallel samples of said DNAs with oligonucleotides specific for alleles of the gene encoding any one of said nucleic acids; and (iii) identifying from among said DNA samples those with a loss of heterozygosity for said alleles, wherein identification of a DNA sample with a loss of heterozygosity indicates presence or a predisposition towards neurological developmental abnormalities. Preferably, the DNA sample is obtained from a human patient, alternatively RNA samples may be obtained and used in the method. Preferably, step (i) may involve amplification of the DNA regions, typically amplification is by PCR. Brief Description of the Figures The invention will now be described by way of example only with reference to the following Figures wherein: Figure 1 represents haplotypes for nine markers from 8p22-pter, for families 1 and 2 segregating autosomal recessive microcephaly. Unaffected siblings from family 1 have been omitted, for clarity. Marker order and relative distances are presented here as deduced from the Genethon map: D8S504-3cM-D8S1824-3cM-D8S1798-3cM- D8S277-2cM-D8S1819-5cM-D8S1825-13cM-D8S552-5cM-D8S1731-5cM- D8S261. Figure 2 represents sequenced BAC's in this region from the human genome project. Position of candidate gene sequences 5R-3V2 (SEQ ID NO:5) and 5G-3V2 (SEQ ID NO:3) shown in blue (numbering corresponding to base-pair position in sequence). Sequenced BACs shown in red. B AC clone contig of [Sun, 1999 #387] shown in black, and STSs derived from this contig shown mapped onto the sequenced BACs by the vertical dashed black lines Figure 3 represents the relationship between SEQ ID NO:l and the sequence variants of SEQ ID NOS :2 to 8 (not to scale). SEQ ID NO:l to 8 represent the nucleic acids of the present invention . SEQ ID NOS: 9 to 16 represent the corresponding protein sequences. Materials and Methods Subjects and Methods A family containing five individuals affected with primary autosomal recessive microcephaly was ascertained. The family originated from the Mirpur region of Pakistan (Fig. 1, family 1). According to the clinical histories, the family confirmed that microcephaly was present from birth in all affected individuals and that there was no history of epilepsy in affected individuals. On examination, head circumferences were 5-9 SD below the population age-related mean. The affected individuals examined were 13-28 years old, and mental retardation ranged from mild to moderate in severity. None were able to read or write, but all could speak and had basic self-care skills. Except for microcephaly, there were no dysmorphic features. No affected individual had a sloping forehead, such as that described by Penrose (Cowie 1960), examination did not reveal weakness, spasticity or athertosis. Computed tomography had been performed on one affected individual at 5 years of age and results were normal. No environmental causes of microcephaly were identified. All parents appeared to be of normal intelligence and had normal head circumferences. A further eight multiply affected consanguineous families were ascertained, with a total of 23 affected individuals displaying primary microcephaly. All of these families also originated from the Mirpur region of Pakistan and had pedigrees consistent with autosomal recessive inheritance. DNA Extraction and Microsatellite Analysis DNA was extracted from peripheral blood lymphocytes by means of a standard nonorganic extraction procedure. The ABI Prism linkage mapping primer set was used to perform a genomewide search. This panel contains 358 microsatellite repeat markers spaced at ~10-cM intervals, with an average heterozygosity of 0.81. PCR amplification of all the autosomal markers was performed according to the manufacturer's specifications. Amplified markers were pooled and electrophoresed on the ABI Prism 377 gene sequencer with a 4.2% polyacrylamide gel at 3000 V and 52°C for 2 h. Fragment-length analysis was performed using the ABI Prism Genescan and Genotyper .1.1.1 analysis packages. For fine mapping on 8p22-pter, D8S504 and D8S277 from the ABI Prism linkage set were used, and a further seven polymorphic markers, from the Genome Database;, were selected: tel-D8S1824-D8S1798-D8S1819~D8S1825-D8S552-D8S1731- D8S261-cen. PCR reactions were performed in 10-μl volumes that contained 50 ng genomic DNA; IμM primers; 250μM each dGTP, dCTP, dTTP, and dATP; 5 U Taq DNA polymerase; and 1 x reaction buffer (1.5-2.0 mM MgCl 2 , lOmM Tris-HCl pH 9.0, 50mM KC1, and 0.1% Triton X-100). Amplification was performed with a 5-min initial denaturing step at 95°C; 35 cycles of 94°C for 30 s, 54°C-60°C for 30 s, and 72°C for 30 s; and a final incubation step at 72°C for 5 in. Linkage Analysis A fully penetrant autosomal recessive mode of inheritance was assumed, and the disease allele frequency was estimated at 1/300. Two-point analysis was performed by the LINKAGE analysis programs (Terwilliger and Ott 1994) and HOMOZ- MAPMAKER was used for multipoint anlaysis (Kruglyak et al. 1995). An allele frequency of 0.1 was used in the genome screen for all markers. For further analysis of the candidate region, marker allele frequencies were calculated by genotyping 34 unrelated individuals from the same ethnic population, with a lower limit for allele frequencies set at 0.1. Heterogeneity testing was performed with the HOMOG program (Morton 1955; Terwilliger and Ott 1994). True Microcephaly was thus mapped to chromosome 8p23 (the MCPHl locus) (Jackson, 1998) using homozygosity mapping to perform a genomewide search. Refinement of the locus was achieved using further fluorescently labelled primers to microsatellite markers in the region. The overlap between the homozygous regions from family 1 and 2 (Figure 1) defined the minimal critical region within which the disease gene lies, between D8S1825 and D8S1824. SEQ ID NO 1 maps to this interval on the basis of radiation hybrid mapping data (Genemap 98, Figure 4). This is additionally confirmed from genomic sequence data (SEQ ID NOS: 1 and 9) derived for the gene, which maps the gene to fully sequenced BACs (Figure 2). These BACs map to the critical region by virtue of containing polymorphic markers mapping within the critical region. Genetic Analysis of Oral Cancers Samples of oral cancers were obtained with local Ethics Committee approval from patients undergoing resections of their tumours. DNA was extracted from 20 such tumours and from the corresponding matched normal tissues, by standard techniques well-known in the art, providing 20 pairs of matched normal and oral cancer DNA specimens. Analysis of these paired specimens for loss of particular genetic loci in the tumours, suggestive of the local presence of a tumour suppressor gene, was performed by use of the polymerase chain reaction. Analysis of known microsatellite markers including D8S1806, D8S1824, D8S1781, D8S1788 and D8S262 (see Figure 2) among others, showed frequent loss of one or both alleles at these loci in the majority of the oral tumours. Loss of heterozygosity was particularly frequent at the genetic markers D8S1824, D8S1781 and D8S1788. The same matched tumour and normal tissue pairs were then compared for alterations in the gene encoding SEQ ID NO:l. In several of these tumours, deletion of both copies of this gene i.e. loss of both alleles, was detected in tumour DNA while PCR products of the expected size were amplified using DNA from matched normal control tissue. In all other cases, the relative amount of PCR amplification product generated using a variety of PCR primer pairs selected within SEQ ID NOS:l to 8, was markedly reduced in the tumour DNA compared with that generated from normal DNA. In cases where one copy of the gene encoding the SEQ ID NO:l was apparently retained in tumour tissue, mutations were detected in the remaining DNA such that the open reading frame encoding the protein of SEQ ID NOS:9 to 16 was disrupted. In every case studied, the change in SEQ ID NOS:l to 8 resulted in the alteration of a codon encoding a normal amino acid to a mis-sense amino acid or termination codon. Thus in these cases, the oral cancer cells were unable to synthesise the protein of SEQ ID NOS:9 to 16; as a result either of deletion of both copies of the gene described in SEQ ID NOS:lto 8 or as a result of deletion of one copy and truncating or mis-sense mutation in 'the residual second copy of the gene. This consistent loss of gene expression in tumours is entirely consistent with a role for the protein in SEQ ID NOS:9 to 16 as a tumour suppressor protein. It also supports the hypothesis that replacement of a functional gene by provision of the nucleic acid sequence described in SEQ ID NOS:l to 8 would have therapeutic utility in the treatment of oral and other cancers demonstrating a similar pattern of loss of heterozygosity. Such patterns have been observed in the past for a number of other human malignancies including prostate cancer, breast cancer, ovarian cancer and colorectal cancer. Thus the nucleic acid of SEQ ID NOS:l to 8 and/or the protein of SEQ ID NOS: 9 to 16 may find equal utility in the treatment of these other common human cancers. Accordingly the nucleic acid molecules and proteins encoded thereby of the present invention and products thereof, are of particular use in gene therapy and in identifying those suffering from or with a predisposition towards cancers, particularly oral cancers and neurological diseases. References 1. Cowie V (1960). The genetics and sub-classification of microcephaly. J Ment. Defic. Res. 4:42-47. 2. Jackson AP, McHale DP, Campbell DA, Jafri H, Rashid Y, Mannan J, Karbani G, Corry P, Levene MI, Mueller RF, Markham AF, Lench NJ, Woods CG (1998). Primary autosomal recessive microcephaly (MCPHl) maps to chromosome 8p22-pter. Am. J. Hum. Genet. 63:541-546. 3. Morton NE (1955). The detection and estimation of linkage between the genes for elliptocytosis and the Rh blood type. Am. J. Hum. Genet 7:80-96. 4. Terwilliger JD, Ott J (1994). Handbook of human genetic linkage. The Johns Hopkins University Press, Baltimore. 5. Kruglyak L, Daly MJ and Lander ES (1995). Rapid multipart linkage analysis of recessive traits in nuclear families, including homozygosity mapping. Am. J. Hum. Genet. 56:519-527. 6. Sun PC, Schmidt AP, Pashima ME, Sunwoo JB and Schlmck SB (1999). Homozygous deletions define a region of 8p23.2 containing a putative tumour suppressor gene. Genomics. 62:184-188. P32093wo

Claims: Claims 1. An isolated nucleic acid, the nucleic acid being selected from the group consisting of: (a) DNAs having the nucleotide sequence given herein as any one of SEQ ID NOS:l to 8; (b) nucleic acids which hybridise to DNAs of (a) above under stringent conditions; (c) nucleic acids having between 75-95% homology with any one of the nucleotide sequences given herein as SEQ ID NOS:l to 8; and (d) nucleic acids which differ from the DNA of (a), (b) or (c) above due to the degeneracy of the genetic. 2. Nucleic acids according to claim 1 wherein the stringent conditions are 1 x SSC, 0.1% SDS at 65 °C. 3. Nucleic acids according to claim 1 consisting essentially of any one of SEQ ID NOS:l to 8. 4. Nucleic acids according to claim 1 which hybridise to any one of SEQ ID NOS:l to 8. 5. Nucleic acids according to claim 1 having between 75-95% homology with any one of the nucleotide sequences given herein as SEQ ID NOS:l to 8. 6. Nucleic acids according to claim 1 which differ from the DNAs of any one of claims 3 to 5. 7. Use of a nucleic acid according to any preceding claim in determining loss of genomic material or loss of expression of mRNA in sample. 8. Use according to claim 7 in detecting the presence of or predisposition towards oral or other cancers and/or neurological developmental abnormalities. 9. Use of a nucleic acid according to any one of claims 1 to 6 in determining the presence of mutants in DNA. 10. Use according to claim 9 in identification of patients suffering from oral or other cancers and/or neurological developmental abnormalities. 11. A polypeptide or a protein encoded by the nucleic acid molecules of any one of claims 1 to 6. 12. A delivery vehicle comprising any one of the isolated nucleic acid molecules of claims 1 to 6 or the polypeptides or proteins encoded thereby or antibodies to these polypeptides or proteins. 13. A delivery vehicle according to claim 12 comprising a viral vector selected from the group comprising an adenovirus, a refrovirus, a herpesvirus, a plasmid, a phage, a phagemid or a liposome 14. A delivery vehicle according to either claim 12 or 13 provided with surface protein adapted to facilitate binding and/or penetration to a specific target. 15. A pharmaceutical composition comprising a nucleic acid according to any one of claims 1 to 6, a polypeptide or protein according to claim 11 and/or the delivery vehicle of any one of claims 12 to 14 and a suitable excipient, diluent or carrier. 16. Antibodies which are specific binding partners of the polypeptide/protein of claim 11 or fragment or derivative thereof which are capable of binding to the antigenic part of the polypeptide/protein. 17. Antibodies according to claim 16 which are monoclonal and/or genetically engineered to be humanised. 18. Use of antibodies or antibody fragments according to either claim 16 or 17 in determining the presence or level of expression of the polypeptide or protein of claim 11. 19. Use of antibodies or antibody fragments according to either claim 16 or 17 or fragments or derivatives thereof in detecting the presence or absence of binding partners whose absence is indicative of oral or other cancers and/or neurological disorders. 20. A method for the treatment of oral cancers and/or neurological disorders comprising administering to a patient suffering from or predisposed to these conditions the nucleic acid molecule of any one of SEQ ID NOS:l to 8 and/or the proteins encoded thereby. 21. A nucleic acid according to any one of claims 1 to 6 or polypeptide or protein of claim 11 or delivery vehicle of any one of claims 12 to 14 for use as a pharmaceutical. 22. A polyamino acid as set forth in any one of SEQ ID NOS: 9-16 for use as a pharmaceutical. 23. Use of the nucleic acids according to any one of claims 1 to 6, for the manufacture of a medicament for the treatment of oral or other cancers and/or neurological disorders. 24. A method of producing a transgenic non-human animal comprising disrupting a gene comprising the nucleic acid of any one of claims 1 to 6, or the effective part thereof, the gene encoding a protein or effective part thereof lack of which is associated with oral or other cancers and/or lack of neurogenesis. 25. A method of producing a transgenic non-human animal comprising preventing expression of a protein or polypeptide of claim 11, or the effective part thereof, lack of expression of the protein being associated with oral or other cancers and/or lack of neurogenesis. 26. A transgenic non-human animal whose somatic and germ cells do not contain or express a gene encoding a nucleic acid according to any one of claims 1 to 6, the gene having been deleted, mutated or disrupted in the animal or an ancestor of the animal at an embryonic stage and wherein the gene may be operably linked to an inducible promoter element. 27. A transgenic non-human animal according to any one of claims 24 to 26 wherein the animal is a rodent. 28. A reporter gene construct based on the promoter region of the gene, or effective part thereof, comprising the nucleic acid of any one of claims 1 to 6. 29. Use of a reporter gene construct based on the promoter region of a gene, or effective part thereof, comprising the nucleic acid of any one of claims 1 to 6 in the detection/screening of pharmaceuticals and/or other compounds. 30. A method of determining the presence of or predisposition towards oral cancer comprising: (i) identifying regions of a DNA sample that contain the nucleic acid according to any one of claims 1 to 6; (ii) individually hybridising parallel samples of said DNAs with oligonucleotides specific for alleles of the gene encoding any one of said nucleic acids; and (iii) identifying from among said DNA samples those with a loss of heterozygosity for said alleles, wherein identification of a DNA sample with a loss of heterozygosity indicates presence or a predisposition towards oral cancer. 31. A modified method according to claim 30 wherein the sample comprises RNA. 32. A method of determining the presence of or predisposition towards neurological developmental abnormalities comprising: (i) identifying regions of a DNA sample that contain the nucleic acid according to any one of claims 1 to 6; (ii) individually hybridising parallel samples of said DNAs with oligonucleotides specific for alleles of the gene encoding any one of said nucleic acids; and (iii) identifying from among said DNA samples those with a loss of heterozygosity for said alleles, wherein identification of a DNA sample with a loss of heterozygosity indicates presence or a predisposition towards neurological developmental abnormalities. 33. A modified method according to claim 32 wherein the sample comprises RNA. 34. A kit comprising the nucleic acids of any one of claims 1 to 6 and a set of instructions for use thereof. SEQ ID NO:1 cDNA sequence (partial) 5.5kb ttttagggatggtatgaatttaatattttttagtattacaatatattcttataaaaaaggtccaagtg aaaaaggcgattgagttgaagtcaagaggagtcaagatgctgcccagcaaggATGGAAGCCATAAAAA CTCTGTCTGGCATATGGAATAACATCAACCATGTGACATCCGAAGAAGATACGTTCATTATGTATCTG GGAAAACCATGGCTTCAAGTGAAAATTCAAGTGAGCCAAGGAGGTGTTGCATTGGTCTCTGACATGTG TCCAGATCCTGGGATTCCAGAAAATGGTAGAAGAGCAGGTTCCGACTTCAGGGTTGGTGCAAATGTAC AGTTTTCATGTGAGGACAATTACGTGCTCCAGGGATCTAAAAGCATCACCTGTCAGAGAGTTACAGAG ACGCTCGCTGCTTGGAGTGACCACAGGCCCATCTGCCGAGCGAGAACATGTGGATCCAATCTGCGTGG GCCCAGCGGCGTCATTACCTCCCCTAATTATCCGGTTCAGTATGAAGATAATGCACACTGTGTGTGGG TCATCACCACCACCGACCCGGACAAGGTCATCAAGCTTGCCTTTGAAGAGTTTGAGCTGGAGCGAGGC TATGACACCCTGACGGTTGGTGATGCTGGGAAGGTGGGAGACACCAGATCGGTCTTGTACGTGCTCAC GGGATCCAGTGTTCCTGACCTCATTGTGAGCATGAGCAACCAGATGTGGCTACATCTGCAGTCGGATG ATAGCATTGGCTCACCTGGGTTTAAAGCTGT.TTACCAAGAAATTGAAAAGGGAGGGTGTGGGGATCCT GGAATCCCCGCCTATGGGAAGCGGACGGGCAGCAGTTTCCTCCATGGAGATACACTCACCTTTGAATG CCCGGCGGCCTTTGAGCTGGTGGGGGAGAGAGTTATCACCTGTCAGCAGAACAATCAGTGGTCTGGCA ACAAGCCCAGCTGTGTATTTTCATGTTTCTTCAACTTTACGGCATCATCTGGGATTATTCTGTCACCA AATTATCCAGAGGAATATGGGAACAACATGAACTGTGTCTGGTTGATTATCTCGGAGCCAGGAAGTCG AATTCACCTAATCTTTAATGATTTTGATGTTGAGCCTCAATTTGACTTTCTCGCGGTCAAGGATGATG GCATTTCTGACATAACTGTCCTGGGTACTTTTTCTGGCAATGAAGTGCCTTCCCAGCTGGCCAGCAGT GGGCATATAGTTCGCTTGGAATTTCAGTCTGACCATTCCACTACTGGCAGAGGGTTCAACATCACTTA CACCACATTTGGTCAGAATGAGTGCCATGATCCTGGCATTCCTATAAACGGACGACGTTTTGGTGACA GGTTTCTACTCGGGAGCTCGGTTTCTTTCCACTGTGATGATGGCTTTGTCAAGACCCAGGGATCCGAG TCCATTACCTGCATACTGCAAGACGGGAACGTGGTCTGGAGCTCCACCGTGCCCCGCTGTGAAGCTCC ATGTGGTGGACATCTGACAGCGTCCAGCGGAGTCATTTTGCCTCCTGGATGGCCAGGATATTATAAGG ATTCTTTACATTGTGAATGGATAATTGAAGCAAAACCAGGCCACTCTATCAAAATAACTTTTGACAGA TTTCAGACAGAGGTCAATTATGACACCTTGGAGGTCAGAGATGGGCCAGCCAGTTCGTCCCCACTGAT CGGCGAGTACCACGGCACCCAGGCACCCCAGTTCCTCATCAGCACCGGGAACTTCATGTACCTGCTAT TCACCACTGACAACAGCCGCTCCAGCATCGGCTTCCTCATCCACTATGAGAGTGTGACGCTTGAGTCG GATTCCTGCCTGGACCCGGGCATCCCTGTGAACGGCCATCGCCACGGTGGAGACTTTGGCATCAGGTG CACAGTGACTTTCAGCTGTGACCCGGGGTACACACTAAGTGACGACGAGCCCCTCGTCTGTGAGAGGA ACCACCAGTGGAACCACGCCTTGCCCAGCTGCGACGCTCTATGTGGAGGCTACATCCAAGGGAAGAGT GGAACAGTCCTTTCTCCTGGGTTTCCAGATTTTTATCCAAACTCTCTAAACTGCACGTGGACCATTGA AGTGTCTCATGGGAAAGGAGTTCAAATGATCTTTCACACCTTTCATCTTGAGAGTTCCCACGACTATT TACTGATCACAGAGGATGGAAGTTTTTCCGAGCCCGTTGCCAGGCTCACCGGGTCGGTGTTGCCTCAT ACGATCAAGGCAGGCCTGTTTGGAAACTTCACTGCCCAGCTTCGGTTTATATCAGACTTCTCAATTTC GTACGAGGGCTTCAATATCACATTTTCAGAATATGACCTGGAGCCATGTGATGATCCTGGAGTCCCTG CCTTCAGCCGAAGAATTGGTTTTCACTTTGGTGTGGGAGACTCTCTGACGTTTTCCTGCTTCCTGGGA TATCGTTTAGAAGGTGCCACCAAGCTTACCTGCCTGGGTGGGGGCCGCCGTGTGTGGAGTGCACCTCT GCCAAGGTGTGTGGCCGAATGTGGAGCAAGTGTCAAAGGAAATGAAGGAACATTACTGTCTCCAAATT TTCCATCCAATTATGATAATAACCATGAGTGTATCTATAAAATAGAAACAGAAGCCGGCAAGGGCATC CACCTTAGAACACGAAGCTTCCAGCTGTTTGAAGGAGATACTCTAAAGGTATATGATGGAAAAGACAG TTCCTCACGTCCACTGGGCACGTTCACTAAAAATGAACTTCTGGGGCTGATCCTAAACAGCACATCCA ATCACCTGTGGCTAGAGTTCAACACCAATGGATCTGACACCGACCAAGGTTTTCAACTCACCTATACC AGTTTTGATCTGGTAAAATGTGAGGATCCGGGCATCCCTAACTACGGCTATAGGATCCGTGATGAAGG CCACTTTACCGACACTGTAGTTCTGTACAGTTGCAACCCGGGGTACGCCATGCATGGCAGCAACACCC TGACCTGTTTGAGTGGAGACAGGAGAGTGTGGGACAAACCACTACCTTCGTGCATAGCGGAATGTGGT GGTCAGATCCATGCAGCCACATCAGGACGAATATTGTCCCCTGGCTATCCAGCTCCGTATGACAACAA CCTCCACTGCACCTGGATTATAGAGGCAGACCCAGGAAAGACCATTAGCCTCCATTTCATTGTTTTCG ACACGGAGATGGCTCACGACATCCTCAAGGTCTGGGACGGGCCGGTGGACAGTGACATCCTGCTGAAG GAGTGGAGTGGCTCCGCCCTTCCGGAGGACATCCACAGCACCTTCAACTCACTCACCCTGCAGTTCGA CAGCGACTTCTTCATCAGCAAGTCTGGCTTCTCCATCCAGTTCTCCACCTCAATTGCAGCCACCTGTA ACGATCCAGGTATGCCCCAAAATGGCACCCGCTATGGAGACAGCAGAGAGGCTGGAGACACCGTCACA TTCCAGTGTGACCCTGGCTATCAGCTCCAAGGACAAGCCAAAATCACCTGTGTGCAGCTGAATAACCG GTTCTTTTGGCAACCAGACCCTCCTACATGCATAGCTGCTTGTGGAGGGAATCTGACGGGCCCAGCAG GTGTTATTTTGTCACCCAACTACCCACAGCCGTATCCTCCTGGGAAGGAATGTGACTGGAGAGTAAAA GTGAACCCGGACTTTGTCATCGCCTTGATATTCAAAAGTTTCAACATGGAGCCCAGCTATGACTTCCT 21 ACACATCTATGAAGGGGAAGATTCCAACAGCCCCCTCATTGGGAGTTACCAGGGCTCTCAGGCCCCAG AAAGAATAGAGAGTAGCGGAAACAGCCTGTTTCTGGCATTTCGGAGTGATGCCTCCGTGGGCCTTTCA GGGTTCGCCATTGAATTTAAAGAGAAACCACGGGAAGCTTGTTTTGACCCAGGAAATATAATGAATGG GACAAGAGTTGGAACAGACTTCAAGCTTGGCTCCACCATCACCTACCAGTGTGACTCTGGCTATAAGA TTCTTGACCCCTCATCCATCACCTGTGTGATTGGGGCTGATGGGAAACCCTCCTGGGACCAAGTGCTG CCCTCCTGCAATGCTCCCTGTGGAGGCCAGTACACGGGATCAGAAGGGGTAGTTTTATCACCAAACTA CCCCCATAATTACACAGCTGGTCAAATATGCCTCTATTCCATCACGGTACCAAAGGAATTCGTGGTCT TTGGACAGTTTGCCTATTTCCAGACAGCCCTGAATGATTTGGCAGAATTATTTGATGGAACCCATGCA CAGGCCAGACTTCTCAGCTCACTCTCGGGGTCTCACTCAGGGGAAACATTGCCCTTGGCTACGTCAAA TCAAATTCTGCTCCGATTCAGTGCAAAGAGCGGTGCCTCTGCCCGCGGCTTCCACTTCGTGTATCAAG CTGTTCCTCGTACCAGTGACACCCAATGCAGCTCTGTCCCCGAGCCCAGATACGGAAGGAGAATTGGT TCTGAGTTTTCTGCCGGCTCCATCGTCCGATTCGAGTGCAACCCGGGATACCTGCTTCAGGGTTCCAC GGCGCTCCACTGCCAGTCCGTGCCCAACGCCTTGGCACAGTGGAACGACACGATCCCCAGCTGTGTGG TACCCTGCAGTGGCAATTTCACTCAACGAAGAGGTACAATCCTGTCCGCCGGCTACCCTGAGCCATAC GGAAACAACTTGAACTGTATATGGAAGATCATAGTTACGGAGGGCTCGGGAATTCAGATCCAAGTGAT CAGTTTTGCCACGGAGCAGAACTGGGACTCCCTTGAGATCCACGATGGTGGGGATGTGACCGCACCCA GACTGGGAAGCTTCTCAGGCACCACAGTACCGGCACTGCTGAACAGTACTTCCAACCAACTCTACCTG CATTTCCAGTCTGACATTAGTGTGGCAGCTGCTGGTTTCCACCTGGAATACAAAACTGTAGGTCTTGC TGCATGCCAAGAACCAGCCCTCCCCAGCAACAGCATCAAAATCGGAGATCGGTACATGGTGAACGACG TGCTCTCCTTCCAGTGCGAGCCCGGGTACACCCTGCAGGGCCGTTCCCACATTTCCTGTATGCCAGGG ACCGTTCGCCGTTGGAACTATCCGTCTCCCCTGTGCATTGCAACCTGTGGAGGGACGCTGAGCACCTT GGGTGGTGTGATCCTGAGCCCCGGCTTCCCAGGTTCTTACCCCAACAACTTAGACTGCACCTGGAGGA TCTCATTACCCATCGGCTATGGTGCACATATTCAGTTTCTGAATTTTTCTACCGAAGCTAATCATGAC" TTCCTTGAAATTCAAAATGGACCTTACCACACCAGCCCCATGATTGGACAATTTAGCGGCACGGATCT CCCCGCGGCCCTGCTGAGCACAACGCATGAAACCCTCATCCACTTTTATAGTGACCATTCGCAAAACC GGCAAGGATTTAAACTTGCTTACCAAGCCTATGAATTACAGAACTGTCCAGATCCACCCCCATTTCAG AATGGGTACATGATCAACTCGGATTACAGCGTGGGGCAATCAGTATCTTTCGAGTGTTATCCTGGGTA CATTCTAATAGGCCATCCTCCG 22 SEQ ID NO:2 G-3V1 Nucleotide sequence 6145 bp 1 TTTTAGGGAT GGTATGAATT TAATATTTTT TAGTATTACA ATATATTCTT 51 ATAAAAAAGG TCCAAGTGAA AAAGGCGATT GAGTTGAAGT CAAGAGGAGT 101 CAAGATGCTG CCCAGCAAGG ATGGAAGCCA TAAAAACTCT GTCTGGCATA 151 TGGAATAACA TCAACCATGT GACATCCGAA GAAGATACGT TCATTATGTA 201 TCTGGGAAAA.CCATGGCTTC AAGTGAAAAT TCAAGTGAGC CAAGGAGGTG 251 TTGCATTGGT CTCTGACATG TGTCCAGATC CTGGGATTCC AGAAAATGGT 301 AGAAGAGCAG GTTCCGACTT CAGGGTTGGT GCAAATGTAC AGTTTTCATG 351 TGAGGACAAT TACGTGCTCC AGGGATCTAA AAGCATCACC TGTCAGAGAG 401 TTACAGAGAC GCTCGCTGCT TGGAGTGACC ACAGGCCCAT CTGCCGAGCG ■ 451 AGAACATGTG GATCCAATCT GCGTGGGCCC AGCGGCGTCA TTACCTCCCC 501 TAATTATCCG GTTCAGTATG AAGATAATGC ACACTGTGTG TGGGTCATCA 551 CCACCACCGA CCCGGACAAG GTCATCAAGC TTGCCTTNGA AGAGTTTGAG 601 CTGGAGCGAG GCTATGACAC CCTNACGGTT GGTGATGCTG GGAAGGTGGG 651 AGACACCAGA TCGGTCTTGT ANGTGCTCAC GGGATCCAGT GTT.CCTGACC 701 TCATTGTGAG CATGAGCAAC CAGATGTGGC TACATCTGCA GTCGGATGAT 751 AGCATTGGCT CACCTGGGTT TAAAGCTGTT TACCAAGAAA TTGAAAAGGG 801 AGGGTGTGGG GATCCTGGAA TCCCCGCCTA TGGGAAGCGG ACGGGCAGCA 851 GTTTCCTCCA TGGAGATACA CTCACCTTTG AATGCCCGGC GGCCTTTGAG 901 CTGGTGGGGG AGAGAGTTAT CACCTGTCAG CAGAACAATC- AGTGGTCTGG 951 CAACAAGCCC AGCTGTGTAT TTTCATGTTT CTTCAACTTT ACGGCATCAT 1001 CTGGGATTAT TCTGTCACCA AATTATCCAG AGGAATATGG GAACAACATG 1051 AACTGTGTCT GGTTGATTAT CTCGGAGCCA GGAAGTCGAA TTCACCTAAT 1101 CTTTAATGAT TTTGATGTTG AGCCTCAATT TGACTTTCTC GCGGTCAAGG 1151 ATGATGGCAT TTCTGACATA ACTGTCCTGG GTACTTTTTC TGGCAATGAA 1201 GTGCCTTCCC AGCTGGCCAG CAGTGGGCAT ATAGTTCGCT TGGAATTTCA 1251 GTCTGACCAT TCCACTACTG GCAGAGGGTT CAACATCACT TACACCACAT 1301 TTGGTCAGAA TGAGTGCCAT GATCCTGGCA TTCCTATAAA CGGACGACGT 1351 TTTGGTGACA GGTTTCTACT CGGGAGCTCG GTTTCTTTCC ACTGTGATGA 1401 TGGCTTTGTC AAGACCCAGG GATCCGAGTC CATTACCTGC ATACTGCAAG 1451 ACGGGAACGT GGTCTGGAGC TCCACCGTGC CCCGCTGTGA AGCTCCATGT 1501 GGTGGACATC TGACAGCGTC CAGCGGAGTC ATTTTGCCTC CTGGATGGCC 1551 AGGATATTAT AAGGATTCTT TACATTGTGA ATGGATAATT GAAGCAAAAC 1601 CAGGCCACTC TATCAAAATA ACTTTTGACA GATTTCAGAC AGAGGTCAAT 1651 TATGACACCT TGGAGGTCAG AGATGGGCCA GCCAGTTCGT CCCCACTGAT 1701 CGGCGAGTAC CACGGCACCC AGGCACCCCA GTTCCTCATC AGCACCGGGA 1751 ACTTCATGTA CCTGCTATTS>.-AGCACTGACA ACAGCCGCTC CAGCATCGGC 1801 TTCCTCATCC ACTATGAGAG TGTGACGCTT GAGTCGGATT CCTGCCTGGA 1851 CCCGGGCATC CCTGTGAACG GCCATCGCCA CGGTGGAGAC TTTGGCATCA 1901 GGTCCACAGT GACTTTCAGC TGTGACCCGG GGTACACACT AAGTGACGAC 1951 GAGCCCCTCG TCTGTGAGAG GAACCACCAG TGGAACCACG CCTTGCCCAG 2001 CTGCGACGCT CTATGTGGAG GCTACATCCA AGGGAAGAGT GGAACAGTCC 2051 TTTCTCCTGG GTTTCCAGAT TTTTATCCAA ACTCTCTAAA CTGCACGTGG 2101 ACCATTGAAG TGTCTCATGG GAAAGGAGTT CAAATGATCT TTCACACCTT 2151 TCATCTTGAG AGTTCCCACG ACTATTTACT GATCACAGAG GATGGAAGTT 2201 TTTCCGAGCC CGTTGCCAGG CTCACCGGGT CGGTGTTGCC TCATACGATC 2251 AAGGCAGGCC TGTTNGGAAA CTTCACTGCC CAGCTTCGGT TTATATCAGA 2301 CTTCTCAATT TCGTACGAGG GCTTCAATAT CACATTTTCA GAATATGACC 2351 TGGAGCCATG TGATGATCCT GGAGTCCCTG CCTTCAGCCG AAGAATTGGT 2401 TTTCACTTTG GTGTGGGAGA CTCTCTGACG TTTTCCTGCT TCCTGGGATA 2451 TCGTTTAGAA GGTGCCACCA AGCTTACCTG CCTGGGTGGG GGCCGCCGTG 2501 TGTGGAGTGC ACCTCTGCCA AGGTGTGTGG CCGAATGTGG AGCAAGTGTC 2551 AAAGGAAATG AAGGAACATT ACTGTCTCCA AATTTTCCAT CCAATTATGA 2601 TAATAACCAT GAGTGTATCT ATAAAATAGA AACAGAAGCC GGCAAGGGCA 2651 TCCACCTTAG AACACGAAGC TTCCAGCTGT TTGAAGGAGA TACTCTAAAG 2701 GTATATGATG GAAAAGACAG TTCCTCACGT CCACTGGGCA CGTTCACTAA 2751 AAATGAACTT CTGGGGCTGA TCCTAAACAG CACATCCAAT CACCTGTGGC 2801 TAGAGTTCAA CACCAATGGA TCTGACACCG ACCAAGGTTT TCAACTCACC 2851 TATACCAGTT TTGATCTGGT AAAATGTGAG GATCCGGGCA TCCCTAACTA 2901 CGGCTATAGG ATCCGTGATG AAGGCCACTT TACCGACACT GTAGTTCTGT 2951 ACAGTTGCAA CCCGGGGTAC GCCATGCATG GCAGCAACAC CCTGACCTGT 3001 TTGAGTGGAG ACAGGAGAGT GTGGGACAAA CCACTACCTT CGTGCATAGC 23 3051 GGAATGTGGT GGTCAGATCC ATGCAGCCAC ATCAGGACGA ATATTGTCCC 3101 CTGGCTATCC AGCTCCGTAT GACAACAACC TCCACTGCAC CTGGATTATA 3151 GAGGCAGACC CAGGAAAGAC CATTAGCCTC CATTTCATTG TTTTCGACAC 3201 GGAGATGGCT CACGACATCC TCAAGGTCTG GGACGGGCCG GTGGACAGTG 3251 ACATCCTGCT GAAGGAGTGG AGTGGCTCCG CCCTTCCGGA GGACATCCAC 3301 AGCACCTTCA ACTCACTCAC CCTGCAGTTC GACAGCGACT TCTTCATCAG 3351 CAAGTCTGGC TTCTCCATCC AGTTCTCCAC CTCAATTGCA GCCACCTGTA 3401 ACGATCCAGG ' TATGCCCCAA AATGGCACCC GCTATGGAGA CAGCAGAGAG 3451 GCTGGAGACA CCGTCACATT CCAGTGTGAC CCTGGCTATC AGCTCCAAGG 3501 ACAAGCCAAA ATCACCTGTG TGCAGCTGAA TAACCGGTTC TTTTGGCAAC 3551 CAGACCCTCC TACATGCATA GCTGCTTGTG GAGGGAATCT GACGGGCCCA 3601 GCAGGTGTTA TTTTGTCACC CAACTACCCA CAGCCGTATC CTCCTGGGAA 3651 GGAATGTGAC TGGAGAGTAA AAGTGAACCC GGACTTTGTC ATCGCCTTGA 3701 TATTCAAAAG TTTCAACATG GAGCCCAGCT ATGACTTCCT ACACATCTAT 3751 GAAGGGGAAG ATTCCAACAG CCCCCTCATT GGGAGTTACC AGGGCTCTCA 3801 GGCCCCAGAA AGAATAGAGA GTAGCGGAAA CAGCCTGTTT CTGGCATTTC 3851 GGAGTGATGC CTCCGTGGGC CTTTCAGGGT TCGCCATTGA ATTTAAAGAG 3901 AAACCACGGG AAGCTTGTTT TGACCCAGGA AATA AATGA ATGGGACAAG 3951 AGTTGGAACA GACTTCAAGC TTGGCTCCAC CATCACCTAC CAGTGTGACT 4001 CTGGCTATAA GATTCTTGAC CCCTCATCCA TCACCTGTGT GATTGGGGCT 4051 GATGGGAAAC CCTCCTGGGA CCAAGTGCTG CCCTCCTGCA ATGCTCCCTG 4101 TGGAGGCCAG TACACGGGAT CAGAAGGGGT AGTTTTATCA CCAAACTACC 4151 CCCATAATTA CACAGCTGGT CAAATATGCC TCTATTCCAT CACGGTACCA 4201 AAGGAATTCG TGGTCTTTGG ACAGTTTGCC TATTTCCAGA CAGCCCTGAA 4251 TGATTTGGCA GAATTATTTG ATGGAACCCA TGCACAGGCC AGACTTCTCA 4301 GCTCACTCTC GGGGTCTCAC TCAGGGGAAA CATTGCCCTT GGCTACGTCA 4351 AATCAAATTC TGCTCCGATT CAGTGCAAAG AGCGGTGCCT CTGCCCGCGG 4401 CTTCCACTTC GTGTATCAAG CTGTTCCTCG TACCAGTGAC ACCCAATGCA 4451 GCTCTGTCCC CGAGCCCAGA TACGGAAGGA GAATTGGTTC TGAGTTTTCT 4501 GCCGGCTCCA TCGTCCGATT CGAGTGCAAC CCGGGATACC TGCTTCAGGG 4551 TTCCACGGCG CTCCACTGCC. AGTCCGTGCC CAACGCCTTG GCAGAGTGGA 4601 ' ACGACACGAT CCCCAGCTGT GTGGTACCCT GCAGTGGCAA TTTCACTCAA 4651 CGAAGAGGTA CAATCCTGTC CCCCGGCTAC CCTGAGCCAT ACGGAAACAA 4701 CTTGAACTGT ATATGGAAGA TCATAGTTAC GGAGGGCTCG GGAATTCAGA 4751 TCCAAGTGAT CAGTTTTGCC ACGGAGCAGA ACTGGGACTC CCTTGAGATC 4801 CACGATGGTG GGGATGTGAC CGCACCCAGA CTGGGAAGCT TCTCAGGCAC 4851 CACAGTACCG GCACTGCTGA ACAGTACTTC CAACCAACTC TACCTGCATT 4901 TCCAGTCTGA CATTAGTGTG GCAGCTGCTG GTTTCCACCT GGAATACAAA 4-951 ACTGTAGGTC TTGCTGCATG CCAAGAACCA GCCCTCCCCA GCAACAGCAT 5001 CAAAATCGGA GATCGGTACA TGGTGAACGA CGTGCTCTCC TTCCAGTGCG 5051 AGCCCGGGTA CACCCTGCAG GGCCGTTCCC ACATTTCCTG TATGCCAGGG 5101 ACCGTTCGCC GTTGGAACTA TCCGTCTCCC CTGTGCATTG CAACCTGTGG 5151 AGGGACGCTG AGCACCTTGG GTGGTGTGAT CCTGAGCCCC GGCTTCCCAG 5201 GTTCTTACCC CAACAACTTA GACTGCACCT GGAGGATCTC ATTACCCATC 5251 GGCTATGGTG CACATATTCA GTTTCTGAAT TTTTCTACCG AAGCTAATCA 5301 TGACTTCCTT GAAATTCAAA ATGGACCTTA CCACACCAGC CCCATGATTG 5351 GACAATTTAG CGGCACGGAT CTCCCCGCGG CCCTGCTGAG CACAACGCAT 5401 GAAACCCTCA TCCACTTTTA TAGTGACCAT TCGCAAAACC GGCAAGGATT 5451 TAAACTTGCT TACCAAGNTA TGGAACAACA ACGAGAACCG AAACCCAAAT 5501 CTAAATACAC TTCTTACATG TAAATTGTAT TTAAGTATAA ATCTCCCTAA 5551 CTGGTTCCAA GCTTGTACGA GTGGAATAAT TTTTTGGTGG AATGTTGGTT 5601 TCTGGTTAGT AGTGGAACAC TTGTTGTTTT TGAAAACAGA GGTAAGGACA 5651 CAGACGGAAC CACCAGTGGG TTCGCCTTTT CTGCTGCCCA GACAGAGCCG 5701 ATTTATCAAG ACGGGAATTG CAATGGAGAA AGAGTAATTC ACGCAGAGCC 5751 AGATGTGTGG GAGACCGGAG TTTTATTGTG ACTCAATTCA GTCTCCCCAG 5801 CATTCAGGGA TTCAAGTTTT TAAAGATAAT TTGGCGGCCG GGCGCGGTGG 5851 CTCACGCCTG TAATCCCAGC ACTTTGGAAG GCCGAGGCGG GCGGATCACG 5901 AGGTCAGGAG ATCGAGACCA TCCTGGCTAA CACGGTGAAA CCCCGTCTCT 5951 ACTAAAAATA CCAAAAATTA GCCGGGCATA GTGGCGGGCG CCTGTAGTCC 6001 CAGCTACTCG GGAGGCTGAG GCAGGANAGT GGCGTGAACC CGGGAGGCGG 6051 AGCTTGCAGT GAGGAGAGAT ■ CGCGCCACTG CACTCCAGCC TGGGCGACAG 6101 AGCCAGACTC CATCTCGAAA AAAAAAAAAA AAAAAAAAAA AAAAA 24 SEQ ID NO:3 G-3V2 Nucleotide sequence 6409 bp 1 TTTTAGGGAT GGTATGAATT TAATATTTTT TAGTATTACA ATATATTCTT 51 ATAAAAAAGG TCCAAGTGAA AAAGGCGATT GAGTTGAAGT CAAGAGGAGT 101 CAAGATGCTG CCCAGCAAGG ATGGAAGCCA TAAAAACTCT. GTCTGGCATA 151 TGGAATAACA TCAACCATGT GACATCCGAA GAAGATACGT TCATTATGTA 201 TCTGGGAAAA CCATGGCTTC AAGTGAAAAT TCAAGTGAGC CAAGGAGGTG 251 TTGCATTGGT CTCT-GACATG TGTCCAGATC CTGGGATTCC AGAAAATGGT 301 AGAAGAGCAG GTTCCGACTT CAGGGTTGGT GCAAATGTAC AGTTTTCATG 351 TGAGGACAAT TACGTGCTCC AGGGATCTAA AAGCATCACC TGTCAGAGAG 401 TTACAGAGAC GCTCGCTGCT TGGAGTGACC ACAGGCCCAT CTGCCGAGCG 451 AGAACATGTG GATCCAATCT GCGTGGGCCC AGCGGCGTCA TTACCTCCCC 501 TAATTATCCG GTTCAGTATG AAGATAATGC ACACTGTGTG TGGGTCATCA 551 CCACCACCGA CCCGGACAAG GTCATCAAGC TTGCCTTNGA AGAGTTTGAG 601 CTGGAGCGAG GCTATGACAC CCTNACGGTT GGTGATGCTG GGAAGGTGGG 651 AGACACCAGA TCGGTCTTGT ANGTGCTCAC GGGATCCAGT GTTCCTGACC 701 TCATTGTGAG CATGAGCAAC CAGATGTGGC TACATCTGCA GTCGGATGAT 751 AGCATTGGCT CACCTGGGTT TAAAGCTGTT TACCAAGAAA TTGAAAAGGG 801 AGGGTGTGGG GATCCTGGAA TCCCCGCCTA TGGGAAGCGG ACGGGCAGCA 851 GTTTCCTCCA TGGAGATACA CTCACCTTTG AATGCCCGGC GGCCTTTGAG 901 CTGGTGGGGG AGAGAGTTAT CACCTGTCAG CAGAACAATC AGTGGTCTGG 951 CAACAAGCCC AGCTGTGTAT TTTCATGTTT CTTCAACTTT ACGGCATCAT 1001 CTGGGATTAT TCTGTCACCA AATTATCCAG AGGAATATGG GAACAACATG 1051 AACTGTGTCT GGTTGATTAT CTCGGAGCCA GGAAGTCGAA TTCACCTAAT 1101 CTTTAATGAT TTTGATGTTG AGCCTCAATT TGACTTTCTC GCGGTCAAGG 1151 ATGATGGCAT TTCTGACATA ACTGTCCTGG GTACTTTTTC TGGCAATGAA 1201 GTGCCTTCCC AGCTGGCCAG CAGTGGGCAT ATAGTTCGCT TGGAATTTCA 1251 GTCTGACCAT TCCACTACTG GCAGAGGGTT CAACATCACT TACACCACAT 1301 TTGGTCAGAA TGAGTGCCAT GATCCTGGCA TTCCTATAAA CGGACGACGT 1351 TTTGGTGACA GGTTTCTACT CGGGAGCTCG GTTTCTTTCC ACTGTGATGA 1401 TGGCTTTGTC AAGACCCAGG GATCCGAGTC CATTACCTGC ATACTGCAAG 1451 ACGGGAACGT GGTCTGGAGC TCCACCGTGC CCCGCTGTGA AGCTCCATGT 1501 GGTGGACATC TGACAGCGTC CAGCGGAGTC ATTTTGCCTC CTGGATGGCC 1551 AGGATATTAT AAGGATTCTT TACATTGTGA ATGGATAATT GAAGCAAAAC 1601 CAGGCCACTC TATCAAAATA ACTTTTGACA GATTTCAGAC AGAGGTCAAT 1651 TATGACACCT TGGAGGTCAG AGATGGGCCA GCCAGTTCGT CCCCACTGAT 1701 CGGCGAGTAC CACGGCACCC AGGCACCCCA GTTCCTCATC AGCACCGGGA 1751 ACTTCATGTA CCTGCTATTC ACCACTGACA ACAGCCGCTC CAGCATCGGC 1801 TTCCTCATCC ACTATGAGAG TGTGACGCTT GAGTCGGATT CCTGCCTGGA 1851 CCCGGGCATC CCTGTGAACG GCCATCGCCA-, CGGTGGAGAC TTTGGCATCA 1901 GGTCCACAGT GACTTTCAGC TGTGACCCGG GGTACACACT AAGTGACGAC 1951 GAGCCCCTCG TCTGTGAGAG GAACCACCAG TGGAACCACG CCTTGCCCAG 2001 CTGCGACGCT CTATGTGGAG GCTACATCCA AGGGAAGAGT GGAACAGTCC 2051 TTTCTCCTGG GTTTCCAGAT TTTTATCCAA ACTCTCTAAA CTGCACGTGG 2101 ACCATTGAAG TGTCTCATGG GAAAGGAGTT CAAATGATCT TTCACACCTT 2151 TCATCTTGAG AGTTCCCACG ACTATTTACT GATCACAGAG GATGGAAGTT 2201 TTTCCGAGCC CGTTGCCAGG CTCACCGGGT CGGTGTTGCC TCATACGATC 2251 AAGGCAGGCC TGTTNGGAAA CTTCACTGCC CAGCTTCGGT TTATATCAGA 2301 CTTCTCAATT TCGTACGAGG GCTTCAATAT CACATTTTCA GAATATGACC 2351 TGGAGCCATG TGATGATCCT GGAGTCCCTG CCTTCAGCCG AAGAATTGGT 2401 TTTCACTTTG GTGTGGGAGA CTCTCTGACG TTTTCCTGCT TCCTGGGATA 2451 TCGTTTAGAA GGTGCCACCA AGCTTACCTG CCTGGGTGGG GGCCGCCGTG 2501 TGTGGAGTGC ACCTCTGCCA AGGTGTGTGG CCGAATGTGG AGCAAGTGTC 2551 AAAGGAAATG AAGGAACATT ACTGTCTCCA AATTTTCCAT CCAATTATGA 2601 TAATAACCAT GAGTGTATCT ATAAAATAGA AACAGAAGCC GGCAAGGGCA 2651 TCCACCTTAG AACACGAAGC TTCCAGCTGT TTGAAGGAGA TACTCTAAAG 2701 GTATATGATG GAAAAGACAG TTCCTCACGT CCACTGGGCA CGTTCACTAA 2751 AAATGAACTT CTGGGGCTGA TCCTAAACAG CACATCCAAT CACCTGTGGC 2801 TAGAGTTCAA CACCAATGGA TCTGACACCG ACCAAGGTTT TCAACTCACC 2851 TATACCAGTT TTGATCTGGT AAAATGTGAG GATCCGGGCA TCCCTAACTA 2901 CGGCTATAGG ATCCGTGATG AAGGCCACTT TACCGACACT GTAGTTCTGT 2951 ACAGTTGCAA CCCGGGGTAC GCCATGCATG GCAGCAACAC CCTGACCTGT 25 3001 TTGAGTGGAG ACAGGAGAGT GTGGGACAAA CCACTACCTT CGTGCATAGC 3051 GGAATGTGGT GGTCAGATCC ATGCAGCCAC ATCAGGACGA ATATTGTCCC 3101 CTGGCTATCC AGCTCCGTAT GACAACAACC TCCACTGCAC CTGGATTATA 3151 GAGGCAGACC CAGGAAAGAC CATTAGCCTC CATTTCATTG TTTTCGACAC 3201 GGAGATGGCT CACGACATCC TCAAGGTCTG GGACGGGCCG GTGGACAGTG 3251 ACATCCTGCT GAAGGAGTGG AGTGGCTCCG CCCTTCCGGA GGACATCCAC 3301 AGCACCTTCA ACTCACTCAC CCTGCAGTTC GACAGCGACT TCTTCATCAG 3351 CAAGTCTGGC ' TTCTCCATCC AGTTCTCCAC CTCAATTGCA GCCACCTGTA 3401 ACGATCCAGG TATGCCCCAA AATGGCACCC GCTATGGAGA CAGCAGAGAG 3451 GCTGGAGACA CCGTCACATT CCAGTGTGAC CCTGGCTATC AGCTCCAAGG 3501 ACAAGCCAAA ATCACCTGTG TGCAGCTGAA TAACCGGTTC TTTTGGCAAC 3551 CAGACCCTCC TACATGCATA GCTGCTTGTG GAGGGAATCT GACGGGCCCA 3601 GCAGGTGTTA TTTTGTCACC CAACTACCCA CAGCCGTATC CTCCTGGGAA 3651 GGAATGTGAC TGGAGAGTAA AAGTGAACCC GGACTTTGTC ATCGCCTTGA 3701 TATTCAAAAG TTTCAACATG GAGCCCAGCT ATGACTTCCT ACACATCTAT 3751 GAAGGGGAAG ATTCCAACAG CCCCCTCATT GGGAGTTACC AGGGCTCTCA 3801 GGCCCCAGAA AGAATAGAGA GTAGCGGAAA CAGCCTGTTT CTGGCATTTC 3851 GGAGTGATGC CTCCGTGGGC CTTTCAGGGT TCGCCATTGA ATTTAAAGAG 3901 AAACCACGGG AAGCTTGTTT TGACCCAGGA AATATAATGA ATGGGACAAG 3951 AGTTGGAACA GACTTCAAGC TTGGCTCCAC CATCACCTAC CAGTGTGACT 4001 CTGGCTATAA GATTCTTGAC CCCTCATCCA TCACCTGTGT GATTGGGGCT 4051 GATGGGAAAC CCTCCTGGGA CCAAGTGCTG CCCTCCTGCA ATGCTCCCTG 4101 ' TGGAGGCCAG TACACGGGAT CAGAAGGGGT AGTTTTATCA CCAAACTACC '4151 CCCATAATTA CACAGCTGGT CAAATATGCC TCTATTCCAT CACGGTACCA 4201 AAGGAATTCG TGGTCTTTGG ACAGTTTGCC TATTTCCAGA CAGCCCTGAA 4251 TGATTTGGCA GAATTATTTG ATGGAACCCA TGCACAGGCC AGACTTCTCA 4301 GCTCACTCTC GGGGTCTCAC TCAGGGGAAA CATTGCCCTT GGCTACGTCA 4351 AATCAAATTC TGCTCCGATT CAGTGCAAAG AGCGGTGCCT CTGCCCGCGG 4401 CTTCCACTTC GTGTATCAAG CTGTTCCTCG TACCAGTGAC ACCCAATGCA 4451 GCTCTGTCCC CGAGCCCAGA TACGGAAGGA GAATTGGTTC TGAGTTTTCT 4501 GCCGGCTCCA TCGTCCGATT CGAGTGCAAC CCGGGATACC TGCTTCAGGG 4551 TTCCACGGCG CTCCACTGCC AGTCCGTGCC CAACGCCTTG GCACAGTGGA 4601 ACGACACGAT CCCCAGCTGT GTGGTACCCT GCAGTGGCAA TTTCACTCAA 4651 CGAAGAGGTA CAATCCTGTC CCCCGGCTAC CCTGAGCCAT ACGGAAACAA 4701 CTTGAACTGT ATATGGAAGA TCATAGTTAC GGAGGGCTCG GGAATTCAGA 4751 TCCAAGTGAT CAGTTTTGCC ACGGAGCAGA ACTGGGACTC CCTTGAGATC 4801 CACGATGGTG GGGATGTGAC CGCACCCAGA CTGGGAAGCT TCTCAGGCAC 4851 CACAGTACCG GCACTGCTGA ACAGTACTTC CAACCAACTC TACCTGCATT 4901 TCCAGTCTGA CATTAGTGTG GCAGCTGCTG GTTTCCACCT GGAATACAAA 4951 ACTGTAGGTC TTGCTGCATG CCAAGAACCA GCCCTCCCCA GCAACAGCAT 5001 CAAAATCGGA GATCGGTACA TGGTGAACGA CGTGCTCTCC TTCCAGTGCG 5051 AGCCCGGGTA CACCCTGCAG GGCCGTTCCC ACATTTCCTG TATGCCAGGG 5101 ACCGTTCGCC GTTGGAACTA TCCGTCTCCC CTGTGCATTG CAACCTGTGG 5151 AGGGACGCTG AGCACCTTGG GTGGTGTGAT CCTGAGCCCC GGCTTCCCAG 5201 GTTCTTACCC CAACAACTTA GACTGCACCT GGAGGATCTC ATTACCCATC 5251 GGCTATGGTG CACATATTCA GTTTCTGAAT TTTTCTACCG AAGCTAATCA 5301 TGACTTCCTT GAAATTCAAA ATGGACCTTA CCACACCAGC CCCATGATTG 5351 GACAATTTAG CGGCACGGAT CTCCCCGCGG CCCTGCTGAG CACAACGCAT 5401 GAAACCCTCA TCCACTTTTA TAGTGACCAT TCGCAAAACC GGCAAGGATT 5451 TAAACTTGCT TACCAAGCCT ATGAATTACA GAACTGTCCA GATCCACCCC 5501 CATTTCAGAA TGGGTACATG ATCAACTCGG ATTACAGCGT GGGGCAATCA 5551 GTATCTTTCG AGTGTTATCC TGGGTACATT CTAATAGGCC ATCCTGTCCT 5601 CACTTGTCAG CATGGGATCA ACAGAAACTG GAACTACCCT TTTCCAAGAT 5651 GTGATGCCCC TTGTGGGTAC AACGTAACTT CTCAGAACGG CACCATCTAC 5701 TCCCCTGGCT TTCCTGATGA GTATCCGATC CTGAAGGACT GCATTTGGCT 5751 CATCACGGTG CCTCCAGGGC ACGGAGTTTA CATCAACTTC ACCCTGTTAC 5801 AGACGGAAGC TGTCAACGAT TACATTGCTG TTTGGGACGG TCCCGATCAG 5851 AACTCACCCC AGCTGGGAGT TTTCAGTGGC AACACAGCCC TCGAAACGGC 5901 GTATAGCTCC ACCAACCAAG TCCTGCTCAA GTTCCACAGC GACTTTTCAA 5951 ATGGAGGCTT CTTTGTCCTC AATTTCCACG GTCAGTTGAT TTTCACTCCG 6001 TTAGTTAAGA CTGAGAATTC CATGTGGTGT TTACTGCAGT GTTGTCCCAC 6051 GCCTTGTTTC CAGCTGAAGT TTCTTGATTC AGCCGAGGGC GTGTATGATT 6101 CTTTTGCACT GGAGGCCAGC GTTTCCTGTG GTCCTTTTTT TGTTTAATGA 26 6151 TGTCTTTATT ATTTCACATC GTATCCAGCT TGGATTTATT CCAAGATACA 6201 TGTATCCTAA GTGAAACTCT AAGATGAAGA CCATTGAAAG AGATTTGGTA 6251 CCTTTTATAG ATTTACTCAT CCCTGTCTCA AGATAAGGTG TTATAGCAAA 6301 TGTCATGTAA CTATAAATGG TGTGAAAGCA AACCTCCAAT AATCCTGGGA 6351 ATGCACTCTA AACGATATGT AGAACATCTG TCAATCNATC GCTTATCTCT 6401 CACGAACAC 27 SEQ ID NO:4 G-3V3 Nucleotide sequence 5667 bp 1 TTTTAGGGAT GGTATGAATT TAATATTTTT TAGTATTACA ATATATTCTT 51 ATAAAAAAGG TCCAAGTGAA AAAGGCGATT GAGTTGAAGT CAAGAGGAGT 101 CAAGATGCTG CCCAGCAAGG ATGGAAGCCA TAAAAACTCT GTCTGGCATA 151 TGGAATAACA .TCAACCATGT GACATCCGAA GAAGATACGT TCATTATGTA 201 TCTGGGAAAA CCATGGCTTC AAGTGAAAAT TCAAGTGAGC CAAGGAGGTG 251 TTGCATTGGT CTCTGACATG TGTCCAGATC CTGGGATTCC AGAAAATGGT 301 AGAAGAGCAG GTTCCGACTT CAGGGTTGGT GCΆAATGTAC AGTTTTCATG 351 TGAGGACAAT TACGTGCTCC AGGGATCTAA AAGCATCACC TGTCAGAGAG 401 TTACAGAGAC GCTCGCTGCT TGGAGTGACC ACAGGCCCAT CTGCCGAGCG 451 AGAACATGTG GATCCAATCT GCGTGGGCCC AGCGGCGTCA TTACCTCCCC 501 TAATTATCCG GTTCAGTATG AAGATAATGC ACACTGTGTG TGGGTCATCA 551 CCACCACCGA CCCGGACAAG GTCATCAAGC TTGCCTTNGA AGAGTTTGAG 601 CTGGAGCGAG GCTATGACAC CCTNACGGTT GGTGATGCTG GGAAGGTGGG 651 AGACACCAGA TCGGTCTTGT ANGTGCTCAC GGGATCCAGT GTTCCTGACC 701 TCATTGTGAG CATGAGCAAC CAGATGTGGC TACATCTGCA GTCGGATGAT 751 AGCATTGGCT CACCTGGGTT TAAAGCTGTT TACCAAGAAA TTGAAAAGGG 801 AGGGTGTGGG GATCCTGGAA TCCCCGCCTA TGGGAAGCGG ACGGGCAGCA 851 GTTTCCTCCA TGGAGATACA CTCACCTTTG AATGCCCGGC GGCCTTTGAG 901 CTGGTGGGGG AGAGAG.TTAT CACCTGTCAG CAGAACAATC AGTGGTCTGG 951 CAACAAGCCC AGCTGTGTAT TTTCATGTTT CTTCAACTTT ACGGCATCAT 1001 CTGGGATTAT TCTGTCACCA AATTATCCAG AGGAATATGG GAACAACATG 1051 AACTGTGTCT GGTTGATTAT CTCGGAGCCA GGAAGTCGAA TTCACCTAAT 1101 CTTTAATGAT TTTGATGTTG AGCCTCAATT TGACTTTCTC GCGGTCAAGG 1151 ATGATGGCAT TTCTGACATA ACTGTCCTGG GTACTTTTTC TGGCAATGAA 1201 GTGCCTTCCC AGCTGGCCAG CAGTGGGCAT ATAGTTCGCT TGGAATTTCA 1251 GTCTGACCAT TCCACTACTG GCAGAGGGTT CAACATCACT TACACCACAT 1301 TTGGTCAGAA TGAGTGCCAT GATCCTGGCA TTCCTATAAA CGGACGACGT 1351 TTTGGTGACA GGTTTCTACT CGGGAGCTCG GTTTCTTTCC ACTGTGATGA 1401 TGGCTTTGTC AAGACCCAGG GATCCGAGTC CATTACCTGC ATACTGCAAG 1451 ACGGGAACGT GGTCTGGAGC TCCACCGTGC CCCGCTGTGA AGCTCCATGT 1501 GGTGGACATC TGACAGCGTC CAGCGGAGTC ATTTTGCCTC CTGGATGGCC 1551 AGGATATTAT AAGGATTCTT TACATTGTGA ATGGATAATT GAAGCAAAAC 1601 CAGGCCACTC TATCAAAATA ACTTTTGACA GATTTCAGAC AGAGGTCAAT 1651 TATGACACCT TGGAGGTCAG AGATGGGCCA GCCAGTTCGT CCCCACTGAT 1701 CGGCGAGTAC CACGGCACCC AGGCACCCCA GTTCCTCATC AGCACCGGGA 1751 ACTTCATGTA CCTGCTATTC ACCACTGACA ACAGCCGCTC CAGCATCGGC 1801 TTCCTCATCC.ACTATGAGAG TGTGACGCTT GAGTCGGATT CCTGCCTGGA 1851 CCCGGGCATC CCTGTGAACG GCCATCGCCA CGGTGGAGAC TTTGGCATCA 1901 GGTCCACAGT GACTTTCAGC TGTGACCCGG GGTACACACT AAGTGACGAC 1951 GAGCCCCTCG TCTGTGAGAG GAACCACCAG TGGAACCACG CCTTGCCCAG 2001 CTGCGACGCT CTATGTGGAG GCTACATCCA AGGGAAGAGT GGAACAGTCC 2051 TTTCTCCTGG GTTTCCAGAT TTTTATCCAA ACTCTCTAAA CTGCACGTGG 2101 ACCATTGAAG TGTCTCATGG GAAAGGAGTT CAAATGATCT TTCACACCTT 2151 TCATCTTGAG AGTTCCCACG ACTATTTACT GATCACAGAG GATGGAAGTT 2201 TTTCCGAGCC CGTTGCCAGG CTCACCGGGT CGGTGTTGCC TCATACGATC 2251 AAGGCAGGCC TGTTNGGAAA CTTCACTGCC CAGCTTCGGT TTATATCAGA 2301 CTTCTCAATT TCGTACGAGG GCTTCAATAT CACATTTTCA GAATATGACC 2351 TGGAGCCATG TGATGATCCT GGAGTCCCTG CCTTCAGCCG AAGAATTGGT 2401 TTTCACTTTG GTGTGGGAGA CTCTCTGACG TTTTCCTGCT TCCTGGGATA 2451 TCGTTTAGAA GGTGCCACCA AGCTTACCTG CCTGGGTGGG GGCCGCCGTG 2501 TGTGGAGTGC ACCTCTGCCA AGGTGTGTGG CCGAATGTGG AGCAAGTGTC 2551 AAAGGAAATG AAGGAACATT ACTGTCTCCA AATTTTCCAT CCAATTATGA 2601 TAATAACCAT GAGTGTATCT ATAAAATAGA AACAGAAGCC GGCAAGGGCA 2651 TCCACCTTAG AACACGAAGC TTCCAGCTGT TTGAAGGAGA TACTCTAAAG 2701 GTATATGATG GAAAAGACAG TTCCTCACGT CCACTGGGCA CGTTCACTAA 2751 AAATGAACTT CTGGGGCTGA TCCTAAACAG CACATCCAAT CACCTGTGGC 2801 TAGAGTTCAA CACCAATGGA TCTGACACCG ACCAAGGTTT TCAACTCACC 2851 TATACCAGTT TTGATCTGGT AAAATGTGAG GATCCGGGCA TCCCTAACTA 2901 CGGCTATAGG ATCCGTGATG AAGGCCACTT TACCGACACT GTAGTTCTGT 2951 ACAGTTGCAA CCCGGGGTAC GCCATGCATG GCAGCAACAC CCTGACCTGT 28 3001 TTGAGTGGAG ACAGGAGAGT GTGGGACAAA CCACTACCTT CGTGCATAGC 3051 GGAATGTGGT GGTCAGATCC ATGCAGCCAC ATCAGGACGA ATATTGTCCC 3101 CTGGCTATCC AGCTCCGTAT GACAACAACC TCCACTGCAC CTGGATTATA 3151 GAGGCAGACC CAGGAAAGAC CATTAGCCTC CATTTCATTG TTTTCGACAC 3201 GGAGATGGCT CACGACATCC TCAAGGTCTG GGACGGGCCG GTGGACAGTG 3251 ACATCCTGCT GAAGGAGTGG AGTGGCTCCG CCCTTCCGGA GGACATCCAC 3301 AGCACCTTCA ACTCACTCAC CCTGCAGTTC GACAGCGACT TCTTCATCAG 3351 CAAGTCTGGC ' TTCTCCATCC AGTTCTCCAC CTCAATTGCA GCCACCTGTA 3401 ACGATCCAGG TATGCCCCAA AATGGCACCC GCTATGGAGA CAGCAGAGAG 3451 GCTGGAGACA CCGTCACATT CCAGTGTGAC CCTGGCTATC AGCTCCAAGG 3501 ACAAGCCAAA ATCACCTGTG TGCAGCTGAA TAACCGGTTC TTTTGGCAAC 3551 CAGACCCTCC TACATGCATA GCTGCTTGTG GAGGGAATCT GACGGGCCCA 3601 GCAGGTGTTA TTTTGTCACC CAACTACCCA CAGCCGTATC CTCCTGGGAA 3651 GGAATGTGAC TGGAGAGTAA AAGTGAACCC GGACTTTGTC ATCGCCTTGA 3701 TATTCAAAAG TTTCAACATG GAGCCCAGCT ATGACTTCCT ACACATCTAT 3751 GAAGGGGAAG ATTCCAACAG " CCCCCTCATT GGGAGTTACC AGGGCTCTCA 3801 GGCCCCAGAA AGAATAGAGA GTAGCGGAAA CAGCCTGTTT CTGGCATTTC 3851 GGAGTGATGC CTCCGTGGGC CTTTCAGGGT TCGCCATTGA ATTTAAAGAG 3901 AAACCACGGG AAGCTTGTTT TGACCCAGGA AAT TAATGA ATGGGACAAG 3951 AGTTGGAACA GACTTCAAGC TTGGCTCCAC CATCACCTAC CAGTGTGACT 4001 CTGGCTATAA GATTCTTGAC CCCTCATCCA TCACCTGTGT GATTGGGGCT 4051 GATGGGAAAC CCTCCTGGGA CCAAGTGCTG CCCTCCTGCA ATGCTCCCTG 4101 TGGAGGCCAG TACACGGGAT CAGAAGGGGT AGTTTTATCA CCAAACTACC 4151 CCCATAATTA CACAGCTGGT CAAATATGCC TCTATTCCAT CACGGTACCA 4201 AAGGAATTCG TGGTCTTTGG ACAGTTTGCC TATTTCCAGA CAGCCCTGAA 4251 TGATTTGGCA GAATTATTTG ATGGAACCCA TGCACAGGCC AGACTTCTCA 4301 GCTCACTCTC GGGGTCTCAC TCAGGGGAAA CATTGCCCTT GGCTACGTCA 4351 AATCAAATTC TGCTCCGATT CAGTGCAAAG AGCGGTGCCT CTGCCCGCGG 4401 CTTCCACTTC GTGTATCAAG CTGTTCCTCG TACCAGTGAC ACCCAATGCA 4451 GCTCTGTCCC CGAGCCCAGA TACGGAAGGA GAATTGGTTC TGAGTTTTCT 4501 GCCGGCTCCA TCGTCCGATT CGAGTGCAAC CCGGGATACC TGCTTCAGGG 4551 TTCCACGGCG CTCCACTGCC AGTCCGTGCC CAACGCCTTG GCACAGTGGA 4601 ACGACACGAT CCCCAGCTGT GTGGTACCCT GCAGTGGCAA TTTCACTCAA 4651 CGAAGAGGTA CAATCCTGTC CCCCGGCTAC CCTGAGCCAT ACGGAAACAA 4701 CTTGAACTGT ATATGGAAGA TCATAGTTAC GGAGGGCTCG GGAATTCAGA 4751 TCCAAGTGAT CAGTTTTGCC ACGGAGCAGA ACTGGGACTC CCTTGAGATC 4801 CACGATGGTG GGGATGTGAC CGCACCCAGA CTGGGAAGCT TCTCAGGCAC 4851 CACAGTACCG GCACTGCTGA ACAGTACTTC CAACCAACTC TACCTGCATT 4901 TCCAGTCTGA CATTAGTGTG GCAGCTGCTG GTTTCCACCT GGAATACAAA 4951 ACTGTAGGTC TTGCTGCATG CCAAGAACCA GCCCTCCCCA GCAACAGCAT 5001 CAAAATCGGA GATCGGTACA TGGTGAACGA CGTGCTCTCC TTCCAGTGCG 5051 AGCCCGGGTA CACCCTGCAG GGCCGTTCCC ACATTTCCTG TATGCCAGGG 5101 ACCGTTCGCC GTTGGAACTA TCCGTCTCCC CTGTGCATTG CAACCTGTGG 5151 AGGGACGCTG AGCACCTTGG GTGGTGTGAT CCTGAGCCCC GGCTTCCCAG 5201 GTTCTTACCC CAACAACTTA GACTGCACCT GGAGGATCTC ATTACCCATC 5251 GGCTATGGTG CACATATTCA GTTTCTGAAT TTTTCTACCG AAGCTAATCA 5301 TGACTTCCTT GAAATTCAAA ATGGACCTTA CCACACCAGC CCCATGATTG 5351 GACAATTTAG CGGCACGGAT CTCCCCGCGG CCCTGCTGAG CACAACGCAT 5401 GAAACCCTCA TCCACTTTTA TAGTGACCAT TCGCAAAACC GGCAAGGATT 5451 TAAACTTGCT TACCAAGCCT AATCTGGAAA CATTGGTCCT GCTTTCCCAT 5501 GTCTTGACAC CCCATTCCAA GCCAGATGTC AAGGAGAAGA AAGGACTTTC 5551 AATTAAAAAA AAAACAAAAA CTCGAAACAA CATGTTTTTT ATTGTACGCC 5601 ATTAATTTCC TATCACTGAG ATATAAAAAT AAATAATGCC NAAAAAAAAA 5651 AAAAAAAAAA AAAAAAA 29 SEQ ID NO:5 R-3V2 Nucleotide sequence 7323 bp 1 GCGTCGGATG CGCGGCGGGT CTTGGGACCG GGCNCTCTCT CCGGCTCGCC 51 TTGCCCTCGG GTGATTATTT GGCTCCGCTC ATAGCCCTGC CTTCCTCGGA 101 GGAGCCATCG GTGTCGCGTG CGTGTGGNGT ATCTGCAGAC ATGACTGCGT 151 GGAGGAGATT . CCAGTCGCTG CTCCTGCTTC TCGGGCTGCT GGTGCTGTGC 201 GCGAGGCTCC TCACTGCAGC GAAGGGTCAG AACTGTGGAG GCTTAGTCCA 251 GGGTCCCAAT GGCACTATTG AGAGCCCAGG GTTTCCTCAC GGGTATCCGA 301 ACTATGCCAA CTGCACCTGG ATCATCATCA CGGGCGAGCG CAATAGGATA 351 CAGTTGTCCT TCCATACCTT TGCTCTTGAA GAAGATTTTG ATATTTTATC 401 AGTTTACGAT GGACAGCCTC AACAAGGGAA TTTAAAAGTG AGATTATCGG 451 GATTTCAGCT GCCCTCCTCT ATAGTGAGTA CAGGATCTAT CCTCACTCTG 501 TGGTTCACGA CAGACTTCGC TGTGAGTGCC CAAGGTTTCA AAGCATTATA 551 TGAAGTTTTA CCTAGCCACA CTTGTGGAAA TCCTGGAGAA ATCCTGAAAG 601 GAGTTCTGCA TGGAACGAGA TTCAACATAG GAGACAANAT CCGGTACAGC 651 TGCCTCCCTG GCTACATCTT GGAAGGCCAC GCCATCCTGA CCTGCATCGT ' 701 CAGCCCAGGA AATGGTGCAT CGTGGGACTT CCCAGCTCCC TTTTGCAGAG 751 CTGAGGGAGC CTGCGGAGGA ACCTTACGCG GGACCAGCAG CTCCATCTCC 801 AGCCCGCACT TCCCTTCAGA GTACGAGAAC AACGCGGACT GCACCTGGAC 851 CATTCTGGCT GAGCCCGGGG ACACCATTGC GCTGGTCTTC ACTGACTTTC 901 AGCTAGAAGA AGGATATGAT TTCTTAGAGA TCAGTGGCAC GGAAGCTCCA 951 TCCATATGGC TAACTGGCAT GAACCTCCCC TCTCCAGTTA TCAGTAGCAA 1001 GAATTGGCTA CGACTCCATT TCACCTCTGA CAGCAACCAC CGACGCAAAG 1051 GATTTAACGC TCAGTTCCAA GTGAAAAAGG CGATTGAGTT GAAGTCAAGA 1101 GGAGTCAAGA TGCTGCCCAG CAAGGATGGA AGCCATAAAA ACTCTGTCTT 1151 GAGCCAAGGA GGTGTTGCAT TGGTCTCTGA CATGTGTCCA GATCCTGGGA 1201 TTCCAGAAAA TGGTAGAAGA GCAGGTTCCG ACTTCAGGGT TGGTGCAAAT 1251 GTACAGTTTT CATGTGAGGA CAATTACGTG CTCCAGGGAT CTAAAAGCAT 1301 CACCTGTCAG AGAGTTACAG AGACGCTCGC TGCTTGGAGT GACCACAGGC 1351 CCATCTGCCG AGCGAGAACA TGTGGATCCA ATCTGCGTGG GCCCAGCGGC 1401 GTCATTACCT CCCCTAATTA TCCGGTTCAG TATGAAGATA ATGCACACTG 1451 TGTGTGGGTC ATCACCACCA CCGACCCGGA CAAGGTCATC AAGCTTGCCT 1501 TNGAAGAGTT TGAGCTGGAG CGAGGCTATG ACACCCTNAC GGTTGGTGAT 1551 GCTGGGAAGG TGGGAGACAC CAGATCGGTC TTGTANGTGC TCACGGGATC 1601 CAGTGTTCCT GACCTCATTG TGAGCATGAG CAACCAGATG TGGCTACATC 1651 TGCAGTCGGA TGATAGCATT GGCTCACCTG GGTTTAAAGC TGTTTACCAA 1701 GAAATTGAAA AGGGAGGGTG TGGGGATCCT GGAATCCCCG CCTATGGGAA 1751 GCGGACGGGC AGCAGTTTCC TCCATGGAGA TNCACTNACC TTTGAATGCC 1801 CGGCGGCCTT TGAGCTGGTG GGGGAGAGAG TTATCACCTG TCAGCAGAAC 1851 AATCAGTGGT CTGGCAACAA GCCCAGCTGT GTATTTTCAT GTTTCTTCAA 1901 CTTTACGGCA TCATCTGGGA TTATTCTGTC ACCAAATTAT CCAGAGGAAT 1951 ATGGGAACAA CATGAACTGT GTCTGGTTGA TTATCTCGGA GCCAGGAAGT 2001 CGAATTCACC TAATCTTTAA TGATTTTGAT GTTGAGCCTC AATTTGACTT 2051 TCTCGCGGTC AAGGATGATG GCATTTCTGA CATAACTGTC CTGGGTACTT 2101 TTTCTGGCAA TGAAGTGCCT TCCCAGCTGG CCAGCAGTGG GCATATAGTT 2151 CGCTTGGAAT TTCAGTCTGA CCATTCCACT ACTGGCAGAG GGTTNAACAT 2201 CACTTACACC ACNTTTGGTC AGAATGAGTG CCATGATCCT GGCATTCCTA 2251 TAAACGGACG ACGTTTTGGT GACAGGTTTC TACTCGGGAG CTCGGTTTCT 2301 TTCCACTGTG ATGATGGCTT TGTCAAGACC CAGGGATCCG AGTCCATTAC 2351 CTGCATACTG CAAGACGGGA ACGTGGTCTG GAGCTCCACC GTGCCCCGCT 2401 GTGAAGCTCC ATGTGGTGGA CATCTGACAG CGTCCAGCGG AGTCATTTTG 2451 CCTCCTGGAT GGCCAGGATA TTATAAGGAT TCTTTACATT GTGAATGGAT 2501 AATTGAAGCA AAACCAGGCC ACTCTATCAA AATAACTTTT GACAGATTTC 2551 AGACAGAGGT CAATTATGAC ACCTTGGAGG TCAGAGATGG GCCAGCCAGT 2601 TCGTCCCCAC TGATCGGCGA GTACCACGGC ACCCAGGCAC CCCAGTTCCT 2651 CATCAGCACC GGGAACTTCA TGTACCTGCT ATTCACCACT GACAACAGCC 2701 GCTCCAGCAT CG.GCTTCCTC ATCCACTATG AGAGTGTGAC GCTTGAGTCG . 2751 GATTCCTGCC TGGACCCGGG CATCCCTGTG AACGGCCATC GCCACGGTGG 2801 AGACTTTGGC ATCAGGTCCA CAGTGACTTT CAGCTGTGAC CCGGGGTACA 2851 CACTAAGTGA CGACGAGCCC CTCGTCTGTG AGAGGAACCA CCAGTGGAAC 2901 CACGCCTTGC CCAGCTGCGA CGCTCTATGT GGAGGCTACA TCCAAGGGAA 2951 GAGTGGAACA GTCCTTTCTC CTGGGTTTCC AGATTTTTAT CCAAACTCTC 30 3001 TAAACTGCAC GTGGACCATT GAAGTGTCTC ATGGGAAAGG AGTTCAAATG 3051 ATCTTTCACA CCTTTCATCT TGAGAGTTCC CACGACTATT TACTGATCAC 3101 AGAGGATGGA AGTTTTTCCG AGCCCGTTGC CAGGCTCACC GGGTCGGTGT 3151 TGCCTCATAC GATCAAGGCA GGCCTGTTNG GAAACTTCAC TGCCCAGCTT 3201 CGGTTTATAT CAGACTTCTC AATTTCGTAC GAGGGCTTCA ATATCACATT 3251 TTCAGAATAT GACCTGGAGC CATGTGATGA TCCTGGAGTC CCTGCCTTCA 3301 GCCGAAGAAT TGGTTTTCAC TTTGGTGTGG GAGACTCTCT GACGTTTTCC 3351 TGCTTCCTGG GATATCGTTT AGAAGGTGCC ACCAAGCTTA CCTGCCTGGG 3401 TGGGGGCCGC CGTGTGTGGA GTGCACCTCT GCCAAGGTGT GTGGCCGAAT 3451 GTGGAGCAAG TGTCAAAGGA AATGAAGGAA CATTACTGTC TCCAAATTTT 3501 CCATCCAATT ATGATAATAA CCATGAGTGT ATCTATAAAA TAGAAACAGA 3551 AGCCGGCAAG GGCATCCACC TTAGAACACG AAGCTTCCAG CTGTTTGAAG 3601 GAGATACTCT AAAGGTATAT GATGGAAAAG ACAGTTCCTC ACGTCCACTG 3651 GGCACGTTCA CTAAAAATGA ACTTCTGGGG CTGATCCTAA ACAGCACATC 3701 CAATCACCTG TGGCTAGAGT TCAACACCAA TGGATCTGAC ACCGACCAAG 3751 GTTTTCAACT CACCTATACC AGTTTTGATC TGGTAAAATG TGAGGATCCG 3801 GGCATCCCTA ACTACGGCTA TAGGATCCGT GATGAAGGCC ACTTTACCGA 3851 CACTGTAGTT CTGTACAGTT GCAACCCGGG GTACGCCATG CATGGCAGCA 3901 ACACCCTGAC CTGTTTGAGT GGAGACAGGA GAGTGTGGGA CAAACCACTA 3951 CCTTCGTGCA TAGCGGAATG TGGTGGTCAG ATCCATGCAG CCACATCAGG 4001 ACGAATATTG TCCCCTGGCT ATCCAGCTCC GTATGACAAC AACCTCCACT 4051 GCACCTGGAT TATAGAGGCA GACCCAGGAA AGACCATTAG CCTCCATTTC 4101 ATTGTTTTCG ACACGGAGAT GGCTCACGAC ATCCTCAAGG TCTGGGACGG 4151 GCCGGTGGAC AGTGACATCC TGCTGAAGGA GTGGAGTGGC TCCGCCCTTC 4201 CGGAGGACAT CCACAGCACC TTCAACTCAC TCACCCTGCA GTTCGACAGC 4251 GACTTCTTCA TCAGCAAGTC TGGCTTCTCC ATCCAGTTCT CCACCTCAAT 4301 TGCAGCCACC TGTAACGATC CAGGTATGCC CCAAAATGGC ACCCGCTATG 4351 GAGACAGCAG AGAGGCTGGA GACACCGTCA CATTCCAGTG TGACCCTGGC 4401 TATCAGCTCC AAGGACAAGC CAAAATCACC TGTGTGCAGC TGAATAACCG 4451 GTTCTTTTGG CAACCAGACC CTCCTACATG CATAGCTGCT TGTGGAGGGA 4501 ATCTGACGGG CCCAGCAGGT GTTATTTTGT CACCCAACTA CCCACAGCCG 4551 TATCCTCCTG GGAAGGAATG TGACTGGAGA GTAAAAGTGA ACCCGGACTT 4601 TGTCATCGCC TTGATATTCA AAAGTTTCAA CATGGAGCCC AGCTATGACT 4651 TCCTACACAT CTATGAAGGG GAAGATTCCA ACAGCCCCCT CATTGGGAGT 4701 TACCAGGGCT CTCAGGCCCC AGAAAGAATA GAGAGTAGCG GAAACAGCCT 4751 GTTTCTGGCA TTTCGGAGTG ATGCCTCCGT GGGCCTTTCA GGGTTCGCCA 4801 TTGAATTTAA AGAGAAACCA CGGGAAGCTT GTTTTGACCC AGGAAATATA 4851 ATGAATGGGA CAAGAGTTGG AACAGACTTC AAGCTTGGCT CCACCATCAC 4901 CTACCAGTGT GACTCTGGCT ATAAGATTCT TGACCCCTCA TCCATCACCT 4951 GTGTGATTGG GGCTGATGGG AAACCCTCCT GGGACCAAGT GCTGCCCTCC 5001 TGCAATGCTC CCTGTGGAGG CCAGTACACG GGATCAGAAG GGGTAGTTTT 5051 ATCACCAAAC TACCCCCATA ATTACACAGC TGGTCAAATA TGCCTCTATT 5101 CCATCACGGT ACCAAAGGAA TTCGTGGTCT TTGGACAGTT TGCCTATTTC 5151 CAGACAGCCC TGAATGATTT GGCAGAATTA TTTGATGGAA CCCATGCACA 5201 GGCCAGACTT CTCAGCTCAC TCTCGGGGTC TCACTCAGGG GAAACATTGC 5251 CCTTGGCTAC GTCAAATCAA ATTCTGCTCC GATTCAGTGC AAAGAGCGGT 5301 GCCTCTGCCC GCGGCTTCCA CTTCGTGTAT CAAGCTGTTC CTCGTACCAG 5351 TGACACCCAA TGCAGCTCTG TCCCCGAGCC CAGATACGGA AGGAGAATTG 5401 GTTCTGAGTT TTCTGCCGGC TCCATCGTCC GATTCGAGTG CAACCCGGGA 5451 TACCTGCTTC AGGGTTCCAC GGCGCTCCAC TGCCAGTCCG TGCCCAACGC 5501 CTTGGCACAG TGGAACGACA CGATCCCCAG CTGTGTGGTA CCCTGCAGTG 5551 GCAATTTCAC TCAACGAAGA GGTACAATCC TGTCCCCCGG CTACCCTGAG 5601 CCATACGGAA ACAACTTGAA CTGTATATGG AAGATCATAG TTACGGAGGG 5651 CTCGGGAATT CAGATCCAAG TGATCAGTTT TGCCACGGAG CAGAACTGGG 5701 " ACTCCCTTGA GATCCACGAT GGTGGGGATG TGACCGCACC CAGACTGGGA 5751 AGCTTCTCAG GCACCACAGT ACCGGCACTG CTGAACAGTA CTTCCAACCA 5801 ACTCTACCTG CATTTCCAGT CTGACATTAG TGTGGCAGCT GCTGGTTTCC 5851 ACCTGGAATA CAAAACTGTA GGTCTTGCTG CATGCCAAGA ACCAGCCCTC 5901 CCCAGCAACA GCATCAAAAT CGGAGATCGG TACATGGTGA ACGACGTGCT 5951 CTCCTTCCAG TGCGAGCCCG GGTACACCCT GCAGGGCCGT TCCCACATTT 6001 CCTGTATGCC AGGGACCGTT CGCCGTTGGA ACTATCCGTC TCCCCTGTGC 6051 ATTGCAACCT GTGGAGGGAC GCTGAGCACC TTGGGTGGTG TGATCCTGAG 6101 CCCCGGCTTC CCAGGTTCTT ACCCCAACAA CTTAGACTGC ACCTGGAGGA 31 6151 TCTCATTACC CATCGGCTAT GGTGCACATA TTCAGTTTCT GAATTTTTCT 6201 ACCGAAGCTA ATCATGACTT CCTTGAAATT CAAAATGGAC CTTACCACAC 6251 CAGCCCCATG ATTGGACAAT TTAGCGGCAC GGATCTCCCC GCGGCCCTGC 6301 TGAGCACAAC GGATGAAACC CTCATCCACT TTTATAGTGA CCATTCGCAA 6351 AACCGGCAAG GATTTAAACT TGCTTACCAA GCCTATGAAT TACAGAACTG 6401 TCCAGATCCA CCCCCATTTC AGAATGGGTA CATGATCAAC TCGGATTACA 6451 GCGTGGGGCA ATCAGTATCT TTCGAGTGTT ATCCTGGGTA CATTCTAATA 6501 GGCCATCCTG ' TCCTCACTTG TCAGCATGGG ATCAACAGAA ACTGGAACTA 6551 CCCTTTTCCA AGATGTGATG CCCCTTGTGG GTACAACGTA ACTTCTCAGA 6601 ACGGCACCAT CTACTCCCCT GGCTTTCCTG ATGAGTATCC GATCCTGAAG 6651 GACTGCATTT GGCTCATCAC GGTGCCTCCA GGGCACGGAG TTTACATCAA 6701 CTTCACCCTG TTACAGACGG AAGCTGTCAA CGATTACATT GCTGTTTGGG 6751 ACGGTCCCGA TCAGAACTCA CCCCAGCTGG GAGTTTTCAG TGGCAACACA 6801 GCCCTCGAAA CGGCGTATAG CTCCACCAAC CAAGTCCTGC TCAAGTTCCA 6851 CAGCGACTTT TCAAATGGAG GCTTCTTTGT CCTCAATTTC CACGGTCAGT 6901 TGATTTTCAC TCCGTTAGTT AAGACTGAGA ATTCCATGTG GTGTTTACTG 6951 CAGTGTTGTC CCACGCCTTG TTTCCAGCTG AAGTTTCTTG ATTCAGCCGA 7001 GGGCGTGTAT GATTCTTTTG CACTGGAGGC CAGCGTTTCC TGTGGTCCTT 7051 TTTTTGTTTA ATGATGTCTT TATTATTTCA CATCGTATCC AGCTTGGATT 7101 TATTCCAAGA TACATGTATC CTAAGTGAAA CTCTAAGATG AAGACCATTG 7151 AAAGAGATTT GGTACCTTTT ATAGATTTAC TCATCCCTGT CTCAAGATAA 7201 GGTGTTATAG CAAATGTCAT GTAACTATAA ATGGTGTGAA AGCAAACCTC 7251 CAATAATCCT GGGAATGCAC TCTAAACGAT ATGTAGAACA TCTGTCAATC 7301 NATCGCTTAT CTCTCACGAA CAC 32 SEQ ID NO:6 5R23V2 AGCTTGTGCCCTTTCCACCTGCATTTCTGATCTAAGTTAGGTAGGGGGCTGCTCTCTGGTC AGCAAGGAAGGGAGATCAAAGGATGGAGGCGGGACTCTGCCCCTGCAGAAACCCTCCAG TTTGCTGGAGTTGCCGGATTACATTGTTCCTCCCCGGTGTGCGGCGTGAGCTTCCCCCACC CGAGCGCCCAACAAGTCTCCTTTCTCCAGCGTGCGCGCTGCTGCGCTGAGGCCGAATGAA GCGCAGCACGGTGCGGGCAGCCCGAGGCCCCGAGGCTGGGCTCTGTCTGTCTGGGACTGC GCCGTGCCCAGCCTCGGTCCCCTCTCTGTGGGTAAGGATGGTTGAGTCCAGCCTCCACGG CAGCGGCTCCTTGTGCCACTAGCAGCCCTTCTTCTGCGCTCTCCGCCTTTTCTCTCTAGAC TGGATCTCTCCTCCCCCCGCGCCCCCCTCCCCGCATCTCCCACTCGCTGGCTCTCTCTCCA GCTGCCTCCTCTCCAGGTCTCTCCTGGCTGCGCGCGCTCCTCTCCCCGCTTCTCCCCCTCCC GCAGCCTCGCCGCCTTGGTGCCTTCCTGCCCGGCTCGGCCGGCGCTCGTCCCCGGCCCCG GCCCCGCCAGCCCGGGTCTCCGCGCTCGGAGCAGCTCAGCCCTGCAGTGGCTCGGGACCC GATGCTATGAGAGGGAAGCGAGCCGGGCGCCCAGACCTTCAGGAGGCGTCGGATGCGCG GCGGGTCTTGGGACCGGGCTCTCTCTCCGGCTCGCCTTGCCCTCGGGTGATTATTTGGCTC CGCTCATAGCCCTGCCTTCCTCGGAGGAGCCATCGGTGTCGCGTGCGTGTGGAGTATCTG CAGACATGACTGCGTGGAGGAGATTCCAGTCGCTGCTCCTGCTTCTCGGGCTGCTGGTGC TGTGCGCGAGGCTCCTCACTGCAGCGAAGGGTCAGAACTGTGGAGGCTTAGTCCAGGGTC CCAATGGCACTATTGAGAGCCCAGGGTTTCCTCACGGGTA ' TCCGAACTATGCCAACTGCA CCTGGATCATCATCACGGGCGAGCGCAATAGGATACAGTTGTCCTTCCATACCTTTGCTCT TGAAGAAGATTTTGATATTTTATCAGTTTACGATGGACAGCCTCAACAAGGGAATTTAAA AGTGAGATTATCGGGATTTCAGCTGCCCTCCTCTATAGTGAGTACAGGATCTATCCTCACT CTGTGGTTCACGACAGACTTCGCTGTGAGTGCCCAAGGTTTCAAAGCATTATATGAAGTT TTACCTAGCCACACTTGTGGAAATCCTGGAGAAATCCTGAAAGGAGTTCTGCATGGAACG AGATTCAACATAGGAGACAANATCCGGTACAGCTGCCTCCCTGGCTACATCTTGGAAGGC CACGCCATCCTGACCTGCATCGTCAGCCCAGGAAATGGTGCATCGTGGGACTTCCCAGCT CCCTTTTGCAGAGCTGAGGGAGCCTGCGGAGGAACCTTACGCGGGACCAGCAGCTCCATC TCCAGCCCGCACTTCCCTTCAGAGTACGAGAACAACGCGGACTGCACCTGGACCATTCTG GCTGAGCCCGGGGACACCATTGCGCTGGTCTTC ACTGACTTTCAGCTAGAAGAAGG ATAT GATTTCTTAGAGATCAGTGGCACGGAAGCTCCATCCATATGGCTAACTGGCATGAACCTC CCCTCTCCAGTTATCAGTAGCAAGAATTGGCTACGACTCCATTTCACCTCTGACAGCAACC ACCGACGCAAAGGATTTAACGCTCAGTTCCAAGTGAAAAAGGCGATTGAGTTGAAGTCA AGAGGAGTCAAGATGCTGCCCAGCAAGGATGGAAGCCATAAAAACTCTGTCTTGAGCCA AGGAGGTGTTGCATTGGTCTCTGACATGTGTCCAGATCCTGGGATTCCAGAAAATGGTAG AAGAGCAGGTTCCGACTTCAGGGTTGGTGCAAATGTACAGTTTTCATGTGAGGACAATTA CGTGCTCCAGGGATCTAAAAGCATCACCTGTCAGAGAGTTACAGAGACGCTCGCTGCTTG GAGTGACCACAGGCCCATCTGCCGAGCGAGAACATGTGGATCCAATCTGCGTGGGCCCAG CGGCGTCATTACCTCCCCTAATTATCCGGTTCAGTATGAAGATAATGCACACTGTGTGTG GGTCATCACCACCACCGACCCGGACAAGGTCATCAAGCTTGCCTTNGAAGAGTTTGAGCT GGAGCGAGGCTATGACACCCTNACGGTTGGTGATGCTGGGAAGGTGGGAGACACCAGAT CGGTCTTGTANGTGCTCACGGGATCCAGTGTTCCTGACCTCATTGTGAGCATGAGCAACC AGATGTGGCTACATCTGCAGTCGGATGATAGCATTGGCTCACCTGGGTTTAAAGCTGTTT ACCAAGAAATTGAAAAGGGAGGGTGTGGGGATCCTGGAATCCCCGCCTATGGGAAGCGG ACGGGCAGCAGTTTCCTCCATGGAGATNCACTNACCTTTGAATGCCCGGCGGCCTTTGAG CTGGTGGGGGAGAGAGTTATCACCTGTCAGCAGAACAATCAGTGGTCTGGCAACAAGCCC AGCTGTGTATTTTCATGTTTCTTCAACTTTACGGCATCATCTGGGATTATTCTGTCACCAA ATTATCCAGAGGAATATGGGAACAACATGAACTGTGTCTGGTTGATTATCTCGGAGCCAG GAAGTCGAATTCACCTAATCTTTAATGATTTTGATGTTGAGCCTCAATTTGACTTTCTCGC GGTCAAGGATGATGGCATTTCTGACATAACTGTCCTGGGTACTTTTTCTGGCAATGAAGT GCCTTCCCAGCTGGCCAGCAGTGGGCATATAGTTCGCTTGGAATTTCAGTCTGACCATTCC ACTACTGGCAGAGGGTTNAACATCACTTACACCACNTTTGGTCAGAATGAGTGCCATGAT CCTGGCATTCCTATAAACGGACGACGTTTTGGTGACAGGTTTCTACTCGGGAGCTCGGTT TCTTTCCACTGTGATGATGGCTTTGTCAAGACCCAGGGATCCGAGTCCATTACCTGCATAC TGCAAGACGGGAACGTGGTCTGGAGCTCCACCGTGCCCCGCTGTGAAGCTCCATGTGGTG GACATCTGACAGCGTCCAGCGGAGTCATTTTGCCTCCTGGATGGCCAGGATATTATAAGG ATTCTTTACATTGTGAATGGATAATTGAAGCAAAACCAGGCCACTCTATCAAAATAACTT 33 TTGACAGATTTCAGACAGAGGTCAATTATGACACCTTGGAGGTCAGAGATGGGCCAGCCA GTTCGTCCCCACTGATCGGCGAGTACCACGGCACCCAGGCACCCCAGTTCCTCATCAGCA CCGGGAACTTCATGTACCTGCTATTCACCACTGACAACAGCCGCTCCAGCATCGGCTTCCT CATCCACTATGAGAGTGTGACGCTTGAGTCGGATTCCTGCCTGGACCCGGGCATCCCTGT GAACGGCCATCGCCACGGTGGAGACTTTGGCATCAGGTCCACAGTGACTTTCAGCTGTGA CCCGGGGTACACACTAAGTGACGACGAGCCCCTCGTCTGTGAGAGGAACCACCAGTGGA ACCACGCCTTGCCCAGCTGCGACGCTCTATGTGGAGGCTACATCCAAGGGAAGAGTGGAA CAGTCCTTTCTCCTGGGTTTCCAGATTTTTATCCAAACTCTCTAAACTGCACGTGGACCAT TGAAGTGTCTCATGGGAAAGGAGTTCAAATGATCTTTCACACCTTTCATCTTGAGAGTTCC CACGACTATTTACTGATCACAGAGGATGGAAGTTTTTCCGAGCCCGTTGCCAGGCTCACC GGGTCGGTGTTGCCTCATACGATCAAGGCAGGCCTGTTNGGAAACTTCACTGCCCAGCTT CGGTTTATATCAGACTTCTCAATTTCGTACGAGGGCTTCAATATCACATTTTCAGAATATG ACCTGGAGCCATGTGATGATCCTGGAGTCCCTGCCTTCAGCCGAAGAATTGGTTTTCACTT TGGTGTGGGAGACTCTCTGACGTTTTCCTGCTTCCTGGGATATCGTTTAGAAGGTGCCACC AAGCTTACCTGCCTGGGTGGGGGCCGCCGTGTGTGGAGTGCACCTCTGCCAAGGTGTGTG GCCGAATGTGGAGCAAGTGTCAAAGGAAATGAAGGAACATTACTGTCTCCAAATTTTCCA TCCAATTATGATAATAACCATGAGTGTATCTATAAAATAGAAACAGAAGCCGGCAAGGGC ATCCACCTTAGAACACGAAGCTTCCAGCTGTTTGAAGGAGATACTCTAAAGGTATATGAT GGAAAAGACAGTTCCTCACGTCCACTGGGCACGTTCACTAAAAATGAACTTCTGGGGCTG ATCCTAAACAGCACATCCAATCACCTGTGGCTAGAGTTCAACACCAATGGATCTGACACC GACCAAGGTTTTCAACTCACCTATACCAGTTTTGATCTGGTAAAATGTGAGGATCCGGGC ATCCCTAACTACGGCTATAGGATCCGTGATGAAGGCCACTTTACCGACACTGTAGTTCTG TACAGTTGCAACCCGGGGTACGCCATGCATGGCAGCAACACCCTGACCTGTTTGAGTGGA GACAGGAGAGTGTGGGACAAACCACTACCTTCGTGCATAGCGGAATGTGGTGGTCAGAT CCATGCAGCCACATCAGGACGAATATTGTCCCCTGGCTATCCAGCTCCGTATGACAACAA CCTCCACTGCACCTGGATTATAGAGGCAGACCCAGGAAAGACCATTAGCCTCCATTTCAT TGTTTTCGACACGGAGATGGCTCACGACATCCTCAAGGTCTGGGACGGGCCGGTGGACAG TGACATCCTGCTGAAGGAGTGGAGTGGCTCCGCCCTTCCGGAGGACATCCACAGCACCTT CAACTCACTCACCCTGCAGTTCGACAGCGACTTCTTCATCAGCAAGTCTGGCTTCTCCATC CAGTTCTCCACCTCAATTGCAGCCACCTGTAACGATCCAGGTATGCCCCAAAATGGCACC CGCTATGGAGACAGCAGAGAGGCTGGAGACACCGTCACATTCCAGTGTGACCCTGGCTAT CAGCTCCAAGGACAAGCCAAAATCACCTGTGTGCAGCTGAATAACCGGTTCTTTTGGCAA CCAGACCCTCCTACATGCATAGCTGCTTGTGGAGGGAATCTGACGGGCCCAGCAGGTGTT ATTTTGTGACCCAACTACCCACAGCCGTATCCTCCTGGGAAGGAATGTGACTGGAGAGTA AAAGTGAACCCGGACTTTGTCATCGCCTTGATATTCAAAAGTTTCAACATGGAGCCCAGC TATGACTTCCTACACATCTATGAAGGGGAAGATTCCAACAGCCCCCTCATTGGGAGTTAC CAGGGCTCTCAGGCCCCAGAAAGAATAGAGAGTAGCGGAAACAGCCTGTTTCTGGCATTT CGGAGTGATGCCTCCGTGGGCCTTTCAGGGTTCGCCATTGAATTTAAAGAGAAACCACGG GAAGCTTGTTTTGACCCAGGAAATATAATGAATGGGACAAGAGTTGGAACAGACTTCAAG CTTGGCTCCACCATCACCTACCAGTGTGACTCTGGCTATAAGATTCTTGACCCCTCATCCA TCACCTGTGTGATTGGGGCTGATGGGAAACCCTCCTGGGACCAAGTGCTGCCCTCCTGCA ATGCTCCCTGTGGAGGCCAGTACACGGGATCAGAAGGGGTAGTTTTATCACCAAACTACC CCCATAATTACACAGCTGGTCAAATATGCCTCTATTCCATCACGGTACCAAAGGAATTCG TGGTCTTTGGACAGTTTGCCTATTTCCAGACAGCCCTGAATGATTTGGCAGAATTATTTGA TGGAACCCATGCACAGGCCAGACTTCTCAGCTCACTCTCGGGGTCTCACTCAGGGGAAAC ATTGCCCTTGGCTACGTCAAATCAAATTCTGCTCCGATTCAGTGCAAAGAGCGGTGCCTCT GCCCGCGGCTTCCACTTCGTGTATCAAGCTGTTCCTCGTACCAGTGACACCCAATGCAGCT CTGTCCCCGAGCCCAGATACGGAAGGAGAATTGGTTCTGAGTTTTCTGCCGGCTCCATCG TCCGATTCGAGTGCAACCCGGGATACCTGCTTCAGGGTTCCACGGCGCTCCACTGCCAGT CCGTGCCCAACGCCTTGGCACAGTGGAACGACACGATCCCCAGCTGTGTGGTACCCTGCA GTGGCAATTTCACTCAACGAAGAGGTACAATCCTGTCCCCCGGCTACCCTGAGCCATACG GAAACAACTTGAACTGTATATGGAAGATCATAGTTACGGAGGGCTCGGGAATTCAGATCC AAGTGATCAGTTTTGCCACGGAGCAGAACTGGGACTCCCTTGAGATCCACGATGGTGGGG ATGTGACCGCACCCAGACTGGGAAGCTTCTCAGGCACCACAGTACCGGCACTGCTGAACA GTACTTCCAACCAACTCTACCTGCATTTCCAGTCTGACATTAGTGTGGCAGCTGCTGGTTT CCACCTGGAATACAAAACTGTAGGTCTTGCTGCATGCCAAGAACCAGCCCTCCCCAGCAA CAGCATCAAAATCGGAGATCGGTACATGGTGAACGACGTGCTCTCCTTCCAGTGCGAGCC 34 CGGGTACACCCTGCAGGGCCGTTCCCACATTTCCTGTATGCCAGGGACCGTTCGCCGTTG GAACTATCCGTCTCCCCTGTGCATTGCAACCTGTGGAGGGACGCTGAGCACCTTGGGTGG TGTGATCCTGAGCCCCGGCTTCCCAGGTTCTTACCCCAACAACTTAGACTGCACCTGGAG GATCTCATTACCCATCGGCTATGGTGCACATATTCAGTTTCTGAATXTTTCTACCGAAGCT AATCATGACTTCCTTGAAATTCAAAATGGACCTTACCACACCAGCCCCATGATTGGACAA TTTAGCGGCACGGATCTCCCCGCGGCCCTGCTGAGCACAACGCATGAAACCCTCATCCAC TTTTATAGTGACCATTCGCAAAACCGGCAAGGATTTAAACTTGCTTACCAAGCCTATGAA TTACAGAACTGTCCAGATCCACCCCCATTTCAGAATGGGTACATGATCAACTCGGATTAC AGCGTGGGGCAATCAGTATCTTTCGAGTGTTATCCTGGGTACATTCTAATAGGCCATCCT GTCCTCACTTGTCAGCATGGGATCAACAGAAACTGGAACTACCCTTTTCCAAGATGTGAT GCCCCTTGTGGGTACAACGTAACTTCTCAGAACGGCACCATCTACTCCCCTGGCTTTCCTG ATGAGTATCCGATCCTGAAGGACTGCATTTGGCTCATCACGGTGCCTCCAGGGCACGGAG TTTACATCAACTTCACCCTGTTACAGACGGAAGCTGTCAACGATTACATTGCTGTTTGGGA CGGTCCCGATCAGAACTCACCCCAGCTGGGAGTTTTCAGTGGCAACACAGCCCTCGAAAC GGCGTATAGCTCCACCAACCAAGTCCTGCTCAAGTTCCACAGCGACTTTTCAAATGGAGG CTTCTTTGTCCTCAATTTCCACGGTCAGTTGATTTTCACTCCGTTAGTTAAGACTGAGAAT TCCATGTGGTGTTTACTGCAGTGTTGTCCCACGCCTTGTTTCCAGCTGAAGTTTCTTGATT CAGCCGAGGGCGTGTATGATTCTTTTGCACTGGAGGCCAGCGTTTCCTGTGGTCCTTTTTT TGTTTAATGATGTCTTTATTATTTCACATCGTATCCAGCTTGGATTTATTCCAAGATACAT GTATCCTAAGTGAAACTCTAAGATGAAGACCATTGAAAGAGATTTGGTACCTTTTATAGA TTTACTCATCCCTGTCTCAAGATAAGGTGTTATAGCAAATGTCATGTAACTATAAATGGTG TGAAAGCAAACCTCCAATAATCCTGGGAATGCACTCTAAACGATATGTAGAACATCTGTC AATCNATCGCTTATCTCTCACGAACACN 35 SEQ ID NO:7 5R2_OC147 AGCTTGTGCCCTTTCCACCTGCATTTCTGATCTAAGTTAGGTAGGGGGCTGCTCTCTGGTCAGCAAGG AAGGGAGATCAAAGGATGGAGGCGGGACTCTGCCCCTGCAGAAACCCTCCAGTTTGCTGGAGTTGCCG GATTACATTGTTCCTCCCCGGTGTGCGGCGTGAGCTTCCCCCACCCGAGCGCCCAACAAGTCTCCTTT CTCCAGCCTGCGCGCTGCTGCGCTGAGGCCGAATGAAGCGCAGCACGGTGCGGGCAGCCCGAGGCCCC GAGGCTGGGCTCTGTCTGTCTGGGACTGCGCCGTGCCCAGCCTCGGTCCCCTCTCTGTGGGTAAGGAT GGTTGAGTCCAGCCTCCACGGCAGCGGCTCCTTGTGCCACTAGCAGCCCTTCTTCTGCGCTCTCCGCC TTTTCT.CTCTAGACTGGATCTCTCCTCCCCCCGCGCCCCCCTCCCCGCATCTCCCACTCGCTGGCTCT CTCTCCAGCTGCCTCCTCTCCAGGTCTCTCCTGGCTGCGCGCGCTCCTCTCCCCGCTTCTCCCCCTCC CGCAGCCTCGCCGCCTTGGTGCCTTCCTGCCCGGCTCGGCCGGCGCTCGTCCCCGGCCCCGGCCCCGC CAGCCCGGGTCTCCGCGCTCGGAGCAGCTCAGCCCTGCAGTGGGTCGGGACCCGATGCTATGAGAGGG AAGCGAGCCGGGCGCCCAGACCTTCAGGAGGCGTCGGATGCGCGGCGGGTCTTGGGACCGGGCTCTCT CTCCGGCTCGCCTTGCCCTCGGGTGATTATTTGGCTCCGCTCATAGCCCTGCCTTCCTCGGAGGAGCC ATCGGTGTCGCGTGCGTGTGGAGTATCTGCAGACATGACTGCGTGGAGGAGATTCCAGTCGCTGCTCC TGCTTCTCGGGCTGCTGGTGCTGTGCGCGAGGCTCCTCACTGCAGCGAAGGGTCAGAACTGTGGAGGC TTAGTCCAGGGTCCCAATGGCACTATTGAGAGCCCAGGGTTTCCTCACGGGTATCCGAACTATGCCAA CTGCACCTGGATCATCATCACGGGCGAGCGCAATAGGATACAGTTGTCCTTCCATACCTTTGCTCTTG AAGAAGATTTTGATATTTTATCAGTTTACGATGGACAGCCTCAACAAGGGAATTTAAAAGTGAGATTA TCGGGATTTCAGCTGCCCTCCTCTATAGTGAGTACAGGATCTATCCTCACTCTGTGGTTCACGACAGA CTTCGCTGTGAGTGCCCAAGGTTTCAAAGCATTATATGAAGTTTTACCTAGCCACACTTGTGGAAATC CTGGAGAAATCCTGAAAGGAGTTCTGCATGGAACGAGATTCAACATAGGAGACAAAATCCGGTACAGC TGCCTCCCTGGCTACATCTTGGAAGGCCACGCCATCCTGACCTGCATCGTCAGCCCAGGAAATGGTGC ATCGTGGGACTTCCCAGCTCCCTTTTGCAGAGCTGAGGGAGCCTGCGGAGGAACCTTACGCGGGACCA GCAGCTCCATCTCCAGCCCGCACTTCCCTTCAGAGTACGAGAACAACGCGGACTGCACCTGGACCATT CTGGCTGAGCCCGGGGACACCATTGCGCTGGTCTTCACTGACTTTCAGCTAGAAGAAGGATATGATTT CTTAGAGATCAGTGGCACGGAAGCTCCATCCATATGGCTAACTGGCATGAACCTCCCCTCTCCAGTTA TCAGTAGCAAGAATTGGCTACGACTCCATTTCACCTCTGACAGCAACCACCGACGCAAAGGATTTAAC GCTCAGTTCCAAGTGAAAAAGGCGATTGAGTTGAAGTCAAGAGGAGTCAAGATGCTGCCCAGCAAGGA TGGAAGCCATAAAAACTCTGTCTGTGAGTCCCTTTCCTTTCTATCTGAGGATTGATACGCCCTTGTAA GCAGAGGAGAGAATGGAGCAGTG 36 SEQ ID NO:8 5R2 AW AGCTTGTGCCCTTTCCACCTGCATTTCTGATCTAAGTTAGGTAGGGGGCTGCTCTCTGGTCAGCAAGG AAGGGAGATCAAAGGATGGAGGCGGGACTCTGCCCCTGCAGAAACCCTCCAGTTTGCTGGAGTTGCCG GATTACATTGTTCCTCCCCGGTGTGCGGCGTGAGCTTCCCCCACCCGAGCGCCCAACAAGTCTCCTTT CTCCAGCCTGCGCGCTGCTGGGCTGAGGCCGAATGAAGCGCAGCACGGTGCGGGCAGCCCGAGGCCCC GAGGCTGGGCTCTGTCTGTCTGGGACTGCGCCGTGCCCAGCCTCGGTCCCCTCTCTGTGGGTAAGGAT GGTTGAGTCCAGCCTCCACGGCAGCGGCTCCTTGTGCCACTAGCAGCCCTTCTTCTGCGCTCTCCGCC TTTTCTCTCTAGACTGGATCTCTCCTCCCCCCGCGCCCCCCTCCCCGCATCTCCCACTCGCTGGCTCT CTCTCCAGCTGCCTCCTCTCCAGGTCTCTCCTGGCTGCGCGCGCTCCTCTCCCCGCTTCTCCCCCTCC CGCAGCCTCGCCGCCTTGGTGCCTTCCTGCCCGGCTCGGCCGGCGCTCGTCCCCGGCCCCGGCCCCGC CAGCCCGGGTCTCCGCGCTCGGAGCAGCTCAGCCCTGCAGTGGCTCGGGACCCGATGCTATGAGAGGG AAGCGAGCCGGGCGCCCAGACCTTCAGGAGGCGTCGGATGCGCGGCGGGTCTTGGGACCGGGCTCTCT CTCCGGCTCGCCTTGCCCTCGGGTGATTATTTGGCTCCGCTCATAGCCCTGCCTTCCTCGGAGGAGCC ATCGGTGTCGCGTGCGTGTGGAGTATCTGCAGACATGACTGCGTGGAGGAGATTCCAGTCGCTGCTCC TGCTTCTCGGGCTGCTGGTGCTGTGCGCGAGGCTCCTCACTGCAGCGAAGGGTCAGAACTGTGGAGGC TTAGTCCAGGGTCCCAATGGCACTATTGAGAGCCCAGGGTTTCCTCACGGGTATCCGAACTATGCCAA CTGCACCTGGATCATCATCACGGGCGAGCGCAATAGGATACAGTTGTCCTTCCATACCTTTGCTCTTG AAGAAGATTTTGATATTTTATCAGTTTACGATGGACAGCCTCAACAAGGGAATTTAAAAGTGAGATTA TCGGGATTTCAGCTGCCCTCCTCTATAGTGAGTACAGGATCTATCCTCACTCTGTGGTTCACGACAGA CTTCGCTGTGAGTGCCCAAGGTTTCAAAGCATTATATGAAGTTTTACCTAGCCACACTTGTGGAAATC CTGGAGAAATCCTGAAAGGAGTTCTGCATGGAACGAGATTCAACATAGGAGACAAAATCCGGTACAGC TGCCTCCCTGGCTACATCTTGGAAGGCCACGCCATCCTGACCTGCATCGTCAGCCCAGGAAATGGTGC ATCGTGGGACTTCCCAGCTCCCTTTTGCAGAGCTGAGGGAGCCTGCGGAGGAACCTTACGCGGGACCA GCAGCTCCATCTCCAGCCCGCACTTCCCTTCAGAGTACGAGAACAACGCGGACTGCACCTGGACCATT CTGGCTGAGCCCGGGGACACCATTGCGCTGGTCTTCACTGACTTTCAGCTAGAAGAAGGATATGATTT CTTAGAGATCAGTGGCACGGAAGCTCCATCCATATGGCTAACTGGCATGAACCTCCCCTCTCCAGTTA TCAGTAGCAAGAATTGGCTACGACTCCATTTCACCTCTGACAGCAACCACCGACGCAAAGGATTTAAC GCTCAGTTCCAAGTGAAAAAGGCGATTGAGTTGAAGTCAAGAGGAGTCAAGATGCTGCCCAGCAAGGA TGGAAGCCATAAAAACTCTGTCTGGCATCAGCAAGAGTTCAGCAAGTGCAGGAAGAAAAAGAGAGAGA TCATGACAAGGAATGGGAGAATTTCCCTGACAGCCTCAGGAAACTTGCAGTTTGATAATTAAACAGAT CAAGGTCACTCAGATGAGCTGATGGGACATGCTGTGTACGGAGGAGCATTTGCAGTTACAACACTTTG TAGCCATGCAGGATGGGGCAATTAATCCAGAACCATTATTTAATAAAAAGATGATTTTTTAAATGTGA AA 37 SEQ ID NO:9 protein sequence >ORF: 121..5598 Frame +1 MEAIKTLSGI NNINHVTSEEDTFIMYLGKPWLQVKIQVSQGGVALVSD CPDPGIPENGRRAGSDFR VGANVQFSCEDNYVLQGSKSITCQRVTETLAAWSDHRPICRARTCGSNLRGPSGVITSPNYPVQYEDN AHCV VITTTDPDKVIKLAFEEFELERGYDTLTVGDAGKVGDTRSVLYVLTGSSVPDLIVSMSNQMWL HLQSDDSIGSPGFKAVYQEIEKGGCGDPGIPAYG RTGSSFLHGDTLTFECPAAFELVGERVITCQQN NQWSGNKPSCVFSCFFNFTASSGIILSPNYPEEYGNNMNCV LIISEPGSRIHLIFNDFDVEPQFDFL AVKDDGISDITVLGTFSGNEVPSQLASSGHIVRLEFQSDHSTTGRGFNITYTTFGQNECHDPGIPING RRFGDRFLLGSSVSFHCDDGFVKTQGSES1TCI QDGNVVWSSTVPRCEAPCGGHLTASSGVILPPG PGYYKDSLHCE IIEAKPGHSIKITFDRFQTEVNYDTLEVRDGPASSSPLIGEYHGTQAPQFLISTGN FMYL FTTDNSRSSIGFLIHYESVTLESDSCLDPGIPVNGHRHGGDFGIRSTVTFSCDPGYTLSDDEP VCERNHQ NHA PSCDA CGGYIQGKSGTVLSPGFPDFYPNS NCTWTIEVSHGKGVQMIFHTFHLE SSHDYLLITEDGSFSEPVARLTGSVLPHTIKAGLFGNFTAQLRFISDFSISYEGFNITFSEYD EPCD DPGVPAFSRRIGFHFGVGDSLTFSCFLGYRLEGATKLTCLGGGRRV SAPLPRCVAECGASVKGNEGT LLSPNFPSNYDNNHECIYKIETEAGKGIHLRTRSFQLFEGDTLKVYDGKDSSSRPLGTFTKNELLGLI NSTSNHLWLEFNTNGSDTDQGFQLTYTSFDLVCEDPGIPNYGYRIRDEGHFTDTVVLYSCNPGYAM HGSNTLTCLSGDRRVWDKPLPSCIAECGGQIHAATSGRI SPGYPAPYDNNLHCTWIIEADPGKTISL HFIVFDTEMAHDILKV DGPVDSDIL KE SGSALPEDIHSTFNS TLQFDSDFFISKSGFSIQFSTS IAATCNDPGMPQNGTRYGDSREAGDTVTFQCDPGYQLQGQAKITCVQLNNRFF QPDPPTCIAACGGN LTGPAGVILSPNYPQPYPPGKECD RVKVNPDFVIALIFKSFNMEPSYDFLHIYEGEDSNSPLIGSYQ GSQAPERIESSGNS FLAFRSDASVGLSGFAIEFKEKPREACFDPGNIMNGTRVGTDFKLGSTITYQC DSGYKILDPSSITCVIGADGKPSWDQVLPSCNAPCGGQYTGSEGWLSPNYPHNYTAGQICLYSITVP KEFVVFGQFAYFQTALNDLAELFDGTHAQAR LSSLSGSHSGETLPLATSNQILLRFSAKSGASARGF HFVYQAVPRTSDTQCSSVPEPRYGRRIGSEFSAGSIVRFECNPGYLLQGSTALHCQSVPNALAQWNDT IPSCWPCSGNFTQRRGTILSPGYPEPYGNNLNCIWKIIVTEGSGIQIQVISFATEQNWDSLEIHDGG DVTAPRLGSFSGT VPALLNSTSNQLYLHFQSDISVAAAGFHLEYKTVGLAACQEPA PSNSIKIGDR YMVNDVLSFQCEPGYTLQGRSHISCMPGTVRRNYPSP CIATCGGTLST GGVILSPGFPGSYPNNL DCTWRISLPIGYGAHIQFLNFSTEANHDFLEIQNGPYHTSPMIGQFSGTDLPAALLSTTHETLIHFYS DHSQNRQGFKLAYQAYELQNCPDPPPFQNGYMINSDYSVGQSVSFECYPGYILIGHPP 38 SEQ ID NO:10 G-3V1 Protein sequence 1801 AA 1 MEAIKTLSGI NNINHVTSE EDTFIMYLGK PWLQVKIQVS QGGVALVSDM 51 CPDPGIPENG RRAGSDFRVG ANVQFSCEDN YVLQGSKSIT CQRVTETLAA 101 SDHRPICRA RTCGSN RGP SGVITSPNYP VQYEDNAHCV WVITTTDPDK 151 VIKLAFEEFE. ERGYDTLTV GDAGVGDTR SVLYVLTGSS VPDLIVSMSN 201 QMWLHLQSDD SIGSPGF AV YQEIEKGGCG DPGIPAYGKR TGSSFLHGDT 251 LTFECPAAFE LVGERVITCQ QNNQWSGNKP SCVFSCFFNF TASSGIILSP 301 NYPEEYGNNM NCVWLIISEP GSRIHLIFND FDVEPQFDFL AVKDDG1SDI 351 TVLGTFSGNE VPSQLASSGH IVRLEFQSDH STTGRGFNIT YTTFGQNECH 401 DPGIPINGRR FGDRFLLGSS VSFHCDDGFV KTQGSESITC ILQDGNVV S 451 STVPRCEAPC GGHLTASSGV ILPPGWPGYY KDSLHCEWII EAKPGHSIKI 501 TFDRFQTEVN YDTLEVRDGP ASSSPLIGEY HGTQAPQFLI STGNFMYLLF 551 TTDNSRSSIG FLIHYESVTL ESDSCLDPGI PVNGHRHGGD FGIRSTVTFS 601 CDPGYTLSDD EP VCERNHQ WNHALPSCDA LCGGYIQGKS GTVLSPGFPD 651 FYPNSLNCTW TIEVSHGKGV QMIFHTFHLE SSHDYLLITE DGSFSEPVAR 701 LTGSVLPHTI KAGLFGNFTA QLRFISDFSI SYEGFNITFS EYD EPCDDP 751 GVPAFSRRIG FHFGVGDSLT FSCFLGYRLE GATKLTCLGG GRRVWSAPLP 801 RCVAECGASV KGNEGTLLS ' P NFPSNYDNNH ECIYK1ETEA GKGIHLRTRS 851 FQLFEGDTLK VYDGKDSSSR PLGTFTKNEL LGLILNSTSN HL LEFNTNG 901 SDTDQGFQLT YTSFDLVKCE DPGIPNYGYR IRDEGHFTDT VVLYSCNPGY 951 AMHGSNTLTC LSGDRRVWDK PLPSC1AECG GQIHAATSGR ILSPGYPAPY 1001 DNNLHCTWII EADPGKTISL HFIVFDTE A HDILKVWDGP VDSDILLKE 1051 SGSALPEDIH STFNSLTLQF DSDFFISKSG FSIQFSTSIA ATCNDPG PQ 1101 NGTRYGDSRE AGDTVTFQCD PGYQLQGQAK ITCVQLNNRF F QPDPPTCI 1151 AACGGNLTGP AGVILSPNYP QPYPPGKECD WRVKVNPDFV 1ALIFKSFNM 1201 EPSYDFLHIY EGEDSNSPLI GSYQGSQAPE RIESSGNSLF LAFRSDASVG 1251 LSGFAIEF E KPREACFDPG NIMNGTRVGT DFKLGSTITY QCDSGYKILD 1301 PSSITCVIGA DGKPSWDQVL PSCNAPCGGQ YTGSEGVVLS PNYPHNYTAG 1351 QICLYSITVP KEFWFGQFA YFQTALNDLA ELFDGTHAQA RLLSSLSGSH 1401 SGETLPLATS NQILLRFSAK SGASARGFHF VYQAVPRTSD TQGSSVPEPR 1451 YGRR1GSEFS AGSIVRFECN PGYLLQGSTA LHCQSVPNAL AQWNDTIPSC 1501 VVPCSGNFTQ RRGTILSPGY PEPYGNNLNC IWKIIVTEGS GIQIQVISFA 1551 TEQN DSLEI HDGGDVTAPR LGSFSGTTVP ALLNSTSNQL YLHFQSDISV 1601 AAAGFHLEYK TVGLAACQEP ALPSNSIKIG DRYMVNDVLS FQCEPGYTLQ 1651 GRSHISCMPG TVRRWNYPSP LCIATCGGTL STLGGVILSP GFPGSYPNNL 1701 DCTWRISLPI GYGAHIQFLN FSTEANHDFL EIQNGPYHTS PMIGQFSGTD 1751 LPAALLSTTH ETLIHFYSDH SQNRQGFKLA YQGMEQQREP KPKSKYTSYM 1801 * 39 SEQ ID NO:ll G-3V2 Protein sequence 2009 AA 1 MEAIKTLSGI WNNINHVTSE EDTFI YLGK PWLQVKIQVS QGGVALVSDM ■ 51 CPDPGIPENG RRAGSDFRVG ANVQFSCEDN YVLQGSKSIT CQRVTETLAA 101 WSDHRPICRA RTCGSNLRGP SGVITSPNYP VQYEDNAHCV WVITTTDPDK 151 VIKLAFEEFE.LERGYDTLTV GDAGKVGDTR SVLYVLTGSS VPDLIVSMSN 201 QMWLHLQSDD SIGSPGFKAV YQEIEKGGCG DPGIPAYGKR TGSSFLHGDT 251 LTFECPAAFE LVGERVITCQ QNNQWSGNKP SCVFSCFFNF TASSGIILSP 301 NYPEEYGNNM NCVWLIISEP GSRIHLIFND FDVEPQFDFL AVKDDGISDI 351 TVLGTFSGNE VPSQLASSGH IVRLEFQSDH STTGRGFNIT YTTFGQNECH 401 DPGIPINGRR FGDRFLLGSS VSFHCDDGFV KTQGSESITC ILQDGNVVWS 451 STVPRCEAPC GGHLTASSGV ILPPGWPGYY KDSLHCEWII EAKPGHSIKI 501 TFDRFQTEVN YDTLEVRDGP ASSSPLIGEY HGTQAPQFLI STGNFMYLLF 551 TTDNSRSSIG FLIHYESVTL ESDSCLDPGI PVNGHRHGGD FGIRSTVTFS 601 CDPGYTLSDD EPLVCERNHQ WNHALPSCDA LCGGYIQGKS GTVLSPGFPD 651 FYPNSLNCTW TIEVSHGKGV QMIFHTFHLE SSHDYLLITE DGSFSEPVAR 701 LTGSVLPHTI KAGLFGNFTA QLRFISDFSI SYEGFNITFS EYDLEPCDDP 751 GVPAFSRRIG FHFGVGDSLT FSCFLGYRLE GATKLTCLGG GRRVWSAPLP 801 RCVAECGASV KGNEGTLLSP NFPSNYDNNH ECIYKIETEA GKGIHLRTRS 851 FQLFEGDTLK VYDGKDSSSR PLGTFTKNEL LGLILNSTSN HLWLEFNTNG 901 SDTDQGFQLT YTSFDLVKCE DPGIPNYGYR IRDEGHFTDT VVLYSCNPGY 951 AMHGSNTLTC LSGDRRVWDK PLPSCIAECG GQIHAATSGR ILSPGYPAPY 1001 DNNLHCTWII EADPGKTISL HFIVFDTEMA HDILKVWDGP VDSDILLKEW 1051 SGSALPEDIH STFNSLTLQF DSDFFISKSG FSIQFSTSIA ATCNDPGMPQ 1101 NGTRYGDSRE AGDTVTFQCD PGYQLQGQAK ITCVQLNNRF FWQPDPPTCI 1151 AACGGNLTGP AGVILSPNYP QPYPPGKECD WRVKVNPDFV IALIFKSFNM 1201 EPSYDFLHIY EGEDSNSPLI GSYQGSQAPE RIESSGNSLF LAFRSDASVG 1251 LSGFAIEFKE KPREACFDPG NIMNGTRVGT DFKLGSTITY QCDSGYKILD 1301 PSSITCVIGA DGKPSWDQVL PSCNAPCGGQ YTGSEGVVLS PNYPHNYTAG 1351 QICLYSITVP KEFVVFGQFA YFQTALNDLA ELFDGTHAQA RLLSSLSGSH 1401 SGETLPLATS NQILLRFSAK SGASARGFHF VYQAVPRTSD TQGSSVPEPR 1451 YGRRIGSEFS AGSIVRFECN PGYLLQGSTA LHCQSVPNAL AQWNDTIPSC 1501 VVPCSGNFTQ RRGTILSPGY PEPYGNNLNC IWKIIVTEGS GIQIQVISFA 1551 TEQNWDSLEI HDGGDVTAPR LGSFSGTTVP ALLNSTSNQL YLHFQSDISV 1601 AAAGFHLEYK TVGLAACQEP ALPSNSIKIG DRYMVNDVLS FQCEPGYTLQ 1651 GRSHISCMPG TVRRWNYPSP LCIATCGGTL STLGGVILSP GFPGSYPNNL 1701 DCTWRISLPI GYGAHIQFLN FSTEANHDFL EIQNGPYHTS PMIGQFSGTD 1751 LPAALLSTTH ETLIHFYSDH SQNRQGFKLA YQAYELQNCP DPPPFQNGYM 1801 INSDYSVGQS VSFECYPGYI LIGHPVLTCQ HGINRNWNYP FPRCDAPCGY 1851 NVTSQNGTIY SPGFPDEYPI LKDCIWLITV PPGHGVYINF TLLQTEAVND 1901 YIAVWDGPDQ NSPQLGVFSG NTALETAYSS TNQVLLKFHS DFSNGGFFVL 1951 NFHGQLIFTP ' LVKTENSMWC LLQCCPTPCF QLKFLDSAEG VYDSFALEAS 2001 VSCGPFFV* 40 SEQ ID NO:12 G-3V3 Protein sequence 1784 AA 1 MEAIKTLSGI WNNINHVTSE EDTFIMYLGK PWLQVKIQVS QGGVALVSDM 51 CPDPGIPENG RRAGSDFRVG ANVQFSCEDN YVLQGSKSIT CQRVTETLAA 101 WSDHRPICRA RTCGSNLRGP SGVITSPNYP VQYEDNAHCV WVITTTDPDK 151 VIKLAFEΞFE.LERGYDTLTV GDAGKVGDTR SVLYVLTGSS VPDLIVSMSN 201 QMWLHLQSDD SIGSPGFKAV YQEIEKGGCG DPGIPAYGKR TGSSFLHGDT 251 LTFECPAAFE LVGERVITCQ QNNQWSGNKP SCVFSCFFNF TASSGIILSP 301 NYPEEYGNNM NCVWLIISEP GSRIHLIFND FDVEPQFDFL AVKDDGISDI 351 TVLGTFSGNE VPSQLASSGH IVRLEFQSDH STTGRGFNIT YTTFGQNECH 401 DPGIPINGRR FGDRFLLGSS VSFHCDDGFV KTQGSESITC ILQDGNVVWS 451 STVPRCEAPC GGHLTASSGV ILPPGWPGYY KDSLHCEWII EAKPGHSIKI 501 TFDRFQTEVN YDTLEVRDGP ASSSPLIGEY HGTQAPQFLI STGNFMYLLF 551 TTDNSRSSIG FLIHYESVTL ESDSCLDPGI PVNGHRHGGD FGIRSTVTFS 601 CDPGYTLSDD EPLVCERNHQ WNHALPSCDA LCGGYIQGKS GTVLSPGFPD 651 FYPNSLNCTW TIEVSHGKGV QMIFHTFHLE SSHDYLLITE DGSFSEPVAR 701 LTGSVLPHTI KAGLFGNFTA QLRFISDFSI SYEGFNITFS EYDLEPCDDP 751 GVPAFSRRIG FHFGVGDSLT FSCFLGYRLE GATKLTCLGG GRRVWSAPLP 801 RCVAECGASV KGNEGTLLSP NFPSNYDNNH ECIYKIETEA GKGIHLRTRS 851 FQLFEGDTLK VYDGKDSSSR PLGTFTKNEL LGLILNSTSN HLWLEFNTNG 901 SDTDQGFQLT YTSFDLVKCE DPGIPNYGYR IRDEGHFTDT VVLYSCNPGY 951 AMHGSNTLTC LSGDRRVWDK PLPSCIAECG GQIHAATSGR ILSPGYPAPY 1001 DNNLHCTWII EADPGKTISL HFIVFDTEMA HDILKVWDGP VDSDILLKEW 1051 SGSALPEDIH STFNSLTLQF DSDFFISKSG FSIQFSTSIA ATCNDPGMPQ 1101 NGTRYGDSRE AGDTVTFQCD PGYQLQGQAK ITCVQLNNRF FWQPDPPTCI 1151 AACGGNLTGP AGVILSPNYP QPYPPGKECD WRVKVNPDFV IALIFKSFNM 1201 EPSYDFLHIY EGEDSNSPLI GSYQGSQAPE RIESSGNSLF LAFRSDASVG 1251 LSGFAIEFKE KPREACFDPG NIMNGTRVGT DFKLGSTITY QCDSGYKILD 1301 PSSITCVIGA DGKPSWDQVL PSCNAPCGGQ YTGSEGVVLS PNYPHNYTAG 1351 QICLYSITVP KEFVVFGQFA YFQTALNDLA ELFDGTHAQA RLLSSLSGSH 1401 SGETLPLATS NQILLRFSAK SGASARGFHF VYQAVPRTSD TQGSSVPEPR 1451 YGRRIGSEFS AGSIVRFECN PGYLLQGSTA LHCQSVPNAL AQWNDTIPSC 1501 VVPCSGNFTQ RRGTILSPGY PEPYGNNLNC IWKIIVTEGS GIQIQVISFA 1551 TEQNWDSLEI HDGGDVTAPR LGSFSGTTVP ALLNSTSNQL YLHFQSDISV 1601 AAAGFHLEYK TVGLAACQEP ALPSNSIKIG DRYMVNDVLS FQCEPGYTLQ 1651 GRSHISCMPG TVRRWNYPSP LCIATCGGTL STLGGV1LSP GFPGSYPNNL 1701 DCTWRISLPI GYGAHIQFLN FSTEANHDFL EIQNGPYHTS PMIGQFSGTD 1751 LPAALLSTTH ETLIHFYSDH SQNRQGFKLA YQA* 41 SEQ ID NO:13 R-3V2 Protein sequence 2353 AA 1 VGCAAGLGTG XSLRLALPSG DYLAPLIALP SSEEPSVSRA CGVSADMTAW 51 RRFQSLLLLL GLLVLCARLL TAAKGQNCGG LVQGPNGTIE SPGFPHGYPN 101 YANCTWIIIT GERNRIQLSF HTFALEEDFD ILSVYDGQPQ QGNLKVRLSG 151 FQLPSSIVST GSILTLWFTT DFAVSAQGFK ALYEVLPSHT CGNPGEILKG 201 VLHGTRFNIG DXIRYSCLPG YILEGHAILT CIVSPGNGAS WDFPAPFCRA 251 EGACGGTLRG TSSSISSPHF PSEYENNADC TWTILAEPGD TIALVFTDFQ 301 LEEGYDFLEI SGTEAPSIWL TGMNLPSPVI SSKNWLRLHF TSDSNHRRKG 351 FNAQFQVKKA IELKSRGVKM LPSKDGSHKN SVLSQGGVAL VSDMCPDPGI 401 PENGRRAGSD FRVGANVQFS CEDNYVLQGS KSITCQRVTE TLAAWSDHRP 451 ICRARTCGSN LRGPSGVITS PNYPVQYEDN AHCVWVITTT DPDKVIKLAF 501 EEFELERGYD TLTVGDAGKV GDTRSVLYVL TGSSVPDLIV SMSNQMWLHL 551 QSDDSIGSPG FKAVYQEIEK GGCGDPGIPA YGKRTGSSFL HGDXLTFECP 601 AAFELVGERV ITCQQNNQWS GNKPSCVFSC FFNFTASSGI ILSPNYPEEY 651 GNNMNCVWLI ISEPGSRIHL IFNDFDVEPQ FDFLAVKDDG ISDITVLGTF 701 SGNEVPSQLA SSGHIVRLEF QSDHSTTGRG XNITYTTFGQ NECHDPGIPI 751 NGRRFGDRFL LGSSVSFHCD DGFVKTQGSE SITCILQDGN WWSSTVPRC 801 EAPCGGHLTA SSGVILPPGW PGYYKDSLHC EWIIEAKPGH SIKITFDRFQ 851 TEVNYDTLEV RDGPASSSPL IGEYHGTQAP QFLISTGNFM YLLFTTDNSR 901 SSIGFLIHYE SVTLESDSCL DPGIPVNGHR HGGDFGIRST VTFSCDPGYT 951 LSDDEPLVCE RNHQWNHALP SCDALCGGYI QGKSGTVLSP GFPDFYPNSL 1001 NCTWTIEVSH GKGVQMIFHT FHLESSHDYL LITEDGSFSE PVARLTGSVL 1051 PHTIKAGLFG NFTAQLRFIS DFSISYEGFN ITFSEYDLEP CDDPGVPAFS 1101 RRIGFHFGVG DSLTFSCFLG YRLEGATKLT CLGGGRRVWS APLPRCVAEC 1151 GASVKGNEGT LLSPNFPSNY DNNHECIYKI ETEAGKGIHL RTRSFQLFEG 1201 DTLKVYDGKD SSSRPLGTFT KNELLGLILN STSNHLWLEF NTNGSDTDQG 1251 FQLTYTSFDL VKCEDPGIPN YGYRIRDEGH FTDTVVLYSC NPGYAMHGSN 1301 TLTCLSGDRR VWDKPLPSCI AECGGQIHAA TSGRILSPGY PAPYDNNLHC 1351 TWIIEADPGK TISLHFIVFD TEMAHDILKV WDGPVDSDIL LKEWSGSALP 1401 EDIHSTFNSL TLQFDSDFFI SKSGFSIQFS TSIAATCNDP GMPQNGTRYG 1451 DSREAGDTVT FQCDPGYQLQ GQAKITCVQL NNRFFWQPDP PTCIAACGGN 1501 LTGPAGVILS PNYPQPYPPG KECDWRVKVN PDFVIALIFK SFNMEPSYDF 1551 LHIYEGEDSN SPLIGSYQGS QAPERIESSG NSLFLAFRSD ASVGLSGFAI 1601 EFKEKPRΞAC FDPGNIMNGT RVGTDFKLGS TITYQCDSGY KILDPSSITC 1651 VIGADGKPSW DQVLPSCNAP CGGQYTGSEG VVLSPNYPHN YTAGQICLYS 1701 ITVPKEFWF GQFAYFQTAL NDLAELFDGT HAQARLLSSL SGSHSGETLP 1751 LATSNQILLR FSAKSGASAR GFHFVYQAVP RTSDTQCSSV PEPRYGRRIG 1801 SEFSAGSIVR FECNPGYLLQ GSTALHCQSV PNALAQWNDT IPSCVVPCSG 1851 NFTQRRGTIL SPGYPEPYGN NLNCIWKIIV TEGSGIQIQV ISFATEQNWD 1901 SLEIHDGGDV TAPRLGSFSG TTVPALLNST SNQLYLHFQS DISVAAAGFH 1951 LEYKTVGLAA CQEPALPSNS IKIGDRYMVN DVLSFQCEPG YTLQGRSHIS 2001 CMPGTVRRWN YPSPLCIATC GGTLSTLGGV ILSPGFPGSY PNNLDCTWRI 2051 SLPIGYGAHI QFLNFSTEAN HDFLEIQNGP YHTSPMIGQF SGTDLPAALL 2101 STTHETLIHF YSDHSQNRQG FKLAYQAYEL QNCPDPPPFQ NGYMINSDYS 2151 VGQSVSFECY PGYILIGHPV LTCQHGINRN WNYPFPRCDA PCGYNVTSQN 2201 GTIYSPGFPD EYPILKDCIW LITVPPGHGV YINFTLLQTE AVNDYIAVWD 2251 GPDQNSPQLG VFSGNTALET AYSSTNQVLL KFHSDFSNGG FFVLNFHGQL 2301 IFTPLVKTEN SMWCLLQCCP TPCFQLKFLD SAEGVYDSFA LEASVSCGPF 2351 FV* 42 SEQ ID NO:14 PROTEIN SEQUENCE 5R23V2 LOCUS 5R23V2.PRO 2307 AA PROT UPDATED 05/11/101 DEFINITION - ACCESSION KEYWORDS SOURCE FEATURES From To/Span Description Peptide ' 1 2307 851 to 7771 of 5R23V2 (translated) ORIGIN ? 1 MTAWRRFQSL LLLLGLLVLC ARLLTAAKGQ -NCGGLVQGPN GTIEΞPGFPH GYPNYANCTW 61 IIITGERNRI QLSFHTFALE EDFDILSVYD GQPQQGNLKV RLSGFQLPSS IVSTGSILTL 121 WFTTDFAVSA QGFKALYEVL PSHTCGNPGE ILKGVLHGTR FNIGDXIRYS CLPGYILEGH 181 AILTCIVSPG NGASWDFPAP FCRAEGACGG T RGTSSSIΞ SPHFPSEYEN NADCTWTILA 241 EPGDTIALVF TDFQLEEGYD FLEIΞGTEAP SIWLTGMNLP SPVISSKNWL RLHFTSDSNH 301 RRKGFNAQFQ VKKAIE KSR GVKMLPSKDG SHKNSVLSQG GVALVSDMCP DPGIPENGRR 361 AGSDFRVGAN VQFSCEDNYV LQGSKSITCQ RVTETLAA S DHRPICRART CGSNLRGPSG 421 VITSPNYPVQ YEDNAHCV V ITTTDPDKVI KLAXEEFELE RGYDTLTVGD AGKVGDTRSV 481 LXVLTGΞΞVP DLIVSMSNQM WLHLQSDDSI GSPGFKAVYQ EIEKGGCGDP GIPAYGKRTG 541 SSFLHGDXLT FECPAAFELV GERVITCQQN NQWSGNKPSC VFSCFFNFTA SSGIILSPNY 601 PEEYGNNMNC VWLIISEPGS RIHLIFNDFD VEPQFDFLAV KDDGISDITV LGTFSGNEVP 661 SQLAΞSGHIV R EFQSDHST TGRGXNITYT TFGQNECHDP GIPINGRRFG DRFLLGSSVS 721 FHCDDGFVKT QGΞESITCIL QDGNVVWSST VPRCEAPCGG HLTASSGVIL PPG PGYYKD 781 SLHCEWIIEA KPGHSIKITF DRFQTEVNYD TLEVRDGPAS SSP IGEYHG TQAPQFLIST 841 GNFMYLLFTT DNSRSΞIGFL IHYESVTLES DSCLDPGIPV NGHRHGGDFG IRSTVTFSCD 901 PGYTLSDDEP LVCERNHQWN HALPSCDALC GGYIQGKSGT VLSPGFPDFY PNSLNCTWTI 961 EVSHGKGVQM IFHTFHLESS HDYLLITEDG SFSEPVARLT GSVLPHTIKA GLXGNFTAQL 1021 RFISDFSISY EGFNITFSEY DLEPCDDPGV PAFSRRIGFH FGVGDSLTFS CFLGYRLEGA 1081 TKLTCLGGGR RVWSAPLPRC VAECGASVKG NEGTLLSPNF PΞNYDNNHEC IYKIETEAGK 1141 GIHLRTRSFQ LFEGDTLKVY DGKDSSSRPL GTFTKNELLG LILNΞTSNHL WLEFNTNGSD 1201 TDQGFQLΓYΓ SFDLVKCEDP GIPNYGYRIR DEGHFTDTW YSCNPGYAM HGSNTLTCLS 1261 GDRRV DKPL PSCIAECGGQ IHAATSGRIL SPGYPAPYDN LHCTWIIEA DPGKTISLHF 1321 IVFDTEMAHD ILKVWDGPVD SDILLKEWSG SALPEDIHST FNSLTLQFDS DFFIΞKSGFS 1381 IQFSTSIAAT CNDPG PQNG TRYGDSREAG DTVTFQCDPG QLQGQAKIT CVQLNNRFFW 1441 QPDPPTCIAA CGGNLTGPAG VILSPNYPQP YPPGKECDWR VKVNPDFVIA IFKSFNMEP 1501 SYDFLHIYEG EDSNSPLIGΞ YQGSQAPERI ESSGNSLFLA FRΞDASVGLS GFAIEFKEKP 1561 REACFDPGNI MNGTRVGTDF KLGSTITYQC DSGYKILDPS SITCVIGADG KPSWDQVLPS 1621 CNAPCGGQYT GSEGVVLSPN YPHNYTAGQI CLYSITVPKE FVVFGQFAYF QTALNDLAEL 1681 FDGTHAQARL LSSLΞGΞHΞG ETLPLATSNQ ILLRFSAKΞG AΞARGFHFVY QAVPRTSDTQ 1741 CΞSVPEPRYG RRIGSEFΞAG SIVRFECNPG YLLQGSTALH. CQSVPNALAQ WNDTIPSCVV 1801 PCSGNFTQRR GTILSPGYPE PYGNNLNCIW KIIVTEGSGI QIQVISFATE QNWDSLEIHD 1861 GGDVTAPRLG SFSGTTVPAL LNSTSNQLYL HFQSDISVAA AGFHLEY TV GLAACQEPAL 1921 PSNSIKIGDR YMVNDVLΞFQ CEPGYTLQGR SHISCMPGTV RRWNYPSPLC IATCGGTLST 1981 LGGVILSPGF PGΞYPNNLDC TWRISLPIGY GAHIQFLNFS TEANHDFLEI QNGPYHTΞPM 2041 IGQFSGTDLP AALLSTTHET LIHFYSDHSQ NRQGFKLAYQ AYELQNCPDP PPFQNGYMIN 2101 ΞDYSVGQSVS FECYPGYILI GHPVLTCQHG INRNWNYPFP RCDAPCGYNV TSQNGTIYSP 2161 GFPDEYPIL DCI LITVPP GHGVYINFTL LQTEAVNDYI AVWDGPDQNS PQLGVFSGNT 2221 ALETAYSSTN QVLLKFHΞDF ΞNGGFFVLNF HGQLIFTPLV KTENΞMWCLL QCCPTPCFQL 2281 KFLDSAEGVY DSFALEASVS CGPFFV* 43 SEQ ID NO: 15 5R2 OC147 PROTEIN LOCUS TRANSLA 10 347 AA PROT UPDATED 05/11/101 DEFINITION ACCESSION KEYWORDS SOURCE FEATURES From To/Span Description Peptide 1 347 851 to 1891 of 5r2 ocl47 (translated) ORIGIN 1 MTA RRFQSL LLLLGLLVLC ARLLTAAKGQ NCGGLVQGPN GTIESPGFPH GYPNYANCTW 61 IIITGERNRI QLSFHTFALE EDFDILSVYD GQPQQGNLKV RLSGFQLPSS IVSTGSILTL 121 WFTTDFAVSA QGFKALYEVL PSHTCGNPGE ILKGVLHGTR FNIGDKIRYS CLPGYILEGH 181 AILTCIVSPG NGASWDFPAP FCRAEGACGG TLRGTSSSIS SPHFPSEYEN NADCTWTILA 241 EPGDTIALVF TDFQLEEGYD FLEISGTEAP SIWLTGMNLP SPVISSKNWL RLHFTSDSNH 301 RRKGFNAQFQ VKKAIELKSR GVK LPSKDG SHKNSVCESL SFLSED* 44 SEQ ID NO:16 5R2 AW PROTEIN LOCUS 5R2_AW_PRO 372 AA PROT UPDATED 05/11/101 DEFINITION - ACCESSION KEYWORDS SOURCE FEATURES From To/Span Description Peptide 1 372 851 to 19 66 of 5r2_aw [translated) ORIGIN ? 1 MTAWRRFQSL LLLLGLLVLC ARLLTAAKGQ NCGGLVQGPN GTIESPGFPH GYPNYANCTW 61 IIITGERNRI QLSFHTFALE EDFDILSVYD GQPQQGNLKV RLSGFQLPSS IVSTGSILTL 121 WFTTDFAVSA QGFKALYEVL PSHTCGNPGE ILKGVLHGTR FNIGDKIRYS CLPGYILEGH 181 AILTCIVSPG NGASWDFPAP FCRAEGACGG TLRGTSSSIS SPHFPSEYEN NADCTWTILA 241 EPGDTIALVF TDFQLEEGYD FLEISGTEAP SIWLTGMNLP SPVISSKNWL RLHFTSDSNH 301 RRKGFNAQFQ VKKAIELKSR GVKMLPSKDG SHKNSVWHQQ EFSKCRKKKR EIMTRNGRIS 361 LTASGNLQFD N* // 45

Inventors: JACKSON ANDREW PETER, MARKHAM ALEXANDER FRED, WOODS CHRISTOPHER GEOFFREY, JACKSON, ANDREW, PETER, MARKHAM, ALEXANDER, FRED, WOODS, CHRISTOPHER, GEOFFREY
Applicants: JACKSON ANDREW PETER, MARKHAM ALEXANDER FRED, UNIV LEEDS, WOODS CHRISTOPHER GEOFFREY, JACKSON, ANDREW, PETER, MARKHAM, ALEXANDER, FRED, UNIVERSITY OF LEEDS, WOODS, CHRISTOPHER, GEOFFREY
Application year: 2001
Main classification: C12N15
IPC codes: A61K38, C07K14, C12N15, C12Q1, G01N33